SEARCH
Search Details
Sho Takuya
| Hokkaido University Hospital Internal Medicine | Assistant Professor |
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
J-Global ID■ Research Keywords and Fields
Research Field■ Educational Organization
- Master's degree program, Graduate School of Medicine
- Doctoral (PhD) degree program, Graduate School of Medicine
Research activity information
■ Papers- Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
Journal of cachexia, sarcopenia and muscle, 17, 3, e70305, Jun. 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features and prognostic impact of cachexia and sarcopenia-alone and combined-in chronic liver disease. METHODS: We retrospectively screened 776 patients with liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC) at Hokkaido University Hospital (August 2014-May 2025). The inclusion criteria were grip strength, CT-based muscle mass and complete clinical data, yielding 307 patients; 469 did not meet one of the inclusion criteria. Cachexia was determined following the Asian Working Group for Cachexia criteria, and sarcopenia was determined following Japan Society of Hepatology guidelines. Patients were grouped as no cachexia/sarcopenia, cachexia only, sarcopenia only or cachexia+sarcopenia. The outcomes were overall survival, time to liver-related events and time to readmission (Kaplan-Meier and Cox-proportional models). RESULTS: Among 776 patients, 307 were included in the final-analysis. Of 307 patients, 206 (67.1%) were male, the median age was 70 years (range, 19-90 years), 262 patients (85.3%) had LC and 188 patients (61.2%) had HCC. The patients were grouped as no cachexia/sarcopenia (213; 69.4%), cachexia only (54; 17.6%), sarcopenia only (17; 5.5%) and cachexia+sarcopenia (23; 7.5%). The combined group compared with the others had the lowest body mass index, psoas-muscle-index and grip strength (all p < 0.001). Overall survival (OS), liver-related events, LC progression and readmissions were compared between 246 patients with and without cachexia or sarcopenia, after excluding those who visited the hospital on or after July 2023 and had ≤ 3 months of follow-up. OS was shorter in the cachexia only (median 61.8 [95% CI 40.90-not reached (NR)] months, p = 0.046) and cachexia+sarcopenia (median 59.6 [95% CI 14.26-NR] months, p = 0.027) groups than in the no cachexia/sarcopenia group. Multivariable analysis showed that cachexia+sarcopenia (hazard ratio 2.48, p = 0.010), HCC (hazard ratio 3.40, p < 0.001) and diabetes mellitus (hazard ratio 1.80, p = 0.013) independently predicted mortality. The combined group compared with the other groups had a shorter time to liver-related events and readmission. CONCLUSIONS: The coexistence of cachexia and sarcopenia-rather than either alone-can be used as an indicator for identifying patients with chronic liver disease at the highest risk of poor outcomes. Concurrent assessment and early, targeted interventions may improve outcomes in this population. - Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.
Masato Nakai; Masatsugu Ohara; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Naohiro Yasuura; Akimitsu Meno; Takashi Kitagataya; Takuya Sho; Goki Suda; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 56, 4, 505, 514, Apr. 2026, [International Magazine]
English, Scientific journal, AIM: In patients with decompensated liver cirrhosis, water retention often leads to complications such as acute kidney injury and poor prognosis. Soluble CD14 (sCD14), a marker of bacterial translocation, may have clinical relevance in this setting. Therefore, we aimed to investigate the prognostic value of sCD14 in patients with decompensated liver cirrhosis and water retention, and to determine its association with diuretic responsiveness, acute kidney injury development, and short-term mortality. METHODS: We retrospectively analyzed 134 patients with decompensated liver cirrhosis and refractory fluid retention treated with tolvaptan. Associations between serum sCD14 levels and diuretic response, acute kidney injury development, and liver-related mortality were evaluated. sCD14 was compared with other bacterial translocation markers (soluble CD163 and mannose receptor) in a subset excluding patients with advanced hepatocellular carcinoma. RESULTS: Lower sCD14 levels were associated with improved short- and long-term diuretic responses and a lower acute kidney injury incidence. Patients with sCD14 ≤ 2340 pg/mL had significantly better liver-related survival than those with higher levels (median survival time: 24.5 vs. 4.8 months, respectively; p < 0.01). In the multivariate analysis, sCD14 > 2340 pg/mL independently predicted liver-related mortality (hazard ratio = 2.71, p < 0.01). Compared with sCD163 and mannose receptor, sCD14 demonstrated superior prognostic value. Concomitant rifaximin use was significantly associated with lower sCD14 levels. CONCLUSIONS: sCD14 is a potential biomarker for predicting prognosis, diuretic response, and acute kidney injury development in patients with decompensated liver cirrhosis and water retention. Its predictive capacity surpasses that of other bacterial translocation markers and may be influenced by administering therapeutic interventions, including rifaximin. - Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.
Goki Suda; Masatsugu Ohara; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Hidetaka Hosono; Daisuke Yokoyama; Shoichi Kitano; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Takaaki Izumi; Ren Yamada; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
The Journal of infection, 92, 4, 106715, 106715, Apr. 2026, [International Magazine]
English, Scientific journal, OBJECTIVE: Our prior interim report remains the only prospective study evaluating tenofovir alafenamide (TAF) for HBV reactivation prevention, with prophylaxis assessed up to 12 months. Herein, we report the final 24-month follow-up results. METHODS: This multicentre prospective-study enrolled HBV carriers who received prophylactic TAF before antineoplastic or immunosuppressive therapy and patients with resolved HBV infection who developed reactivation and received TAF as reactivation-related hepatitis prophylaxis. We examined TAF effectiveness at 12 and 24 months. The primary endpoints were HBV reactivation and reactivation-related hepatitis. RESULTS: Of 191 enrolled patients, 150 and 127 were evaluable at 12 and 24 months, respectively. At 12 months, no HBV reactivation, HBV reactivation-related hepatitis, or therapy interruption occurred. Between months 12-24, four patients discontinued TAF. None of the remaining patients experienced HBV reactivation, HBV reactivation-related-hepatitis, or treatment interruption. Virologic relapse occurred in one of two patients with TAF discontinuation after anticancer/immunosuppressive therapy completion; TAF re-initiation enabled biochemical hepatitis prevention and viral suppression. Neither patient who switched to entecavir experienced reactivation. No patients on high-risk regimens developed reactivation, reactivation-related hepatitis, or treatment interruption. No patient discontinued therapy for TAF-related adverse events. CONCLUSIONS: Over 24 months, TAF demonstrated effectiveness in preventing HBV reactivation and reactivation-related hepatitis. - Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.
Goki Suda; Masatsugu Ohara; Masato Nakai; Takuya Sho; Naoya Sakamoto
European journal of cancer (Oxford, England : 1990), 237, 116580, 116580, 26 Mar. 2026, [International Magazine]
English - Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.
Federica Lo Prinzi; Federico Rossari; Antonio De Rosa; Caterina Vivaldi; Masatoshi Kudo; Shigeo Shimose; Goki Suda; Silvia Camera; Silvia Foti; Mario Domenico Rizzato; Francesca Salani; Naoshi Nishida; Tomotake Shirono; Naoya Sakamoto; Laura Passeri; Michele Ferrara; Caterina Soldà; Silvia Cesario; Kazuomi Ueshima; Takashi Niizeki; Takuya Sho; Mara Persano; Francesco Vitiello; Federica Invernizzi; Sara Lonardi; Gianluca Masi; Margherita Rimini; Andrea Casadei Gardini
Hepatology research : the official journal of the Japan Society of Hepatology, 56, 3, 377, 386, Mar. 2026, [International Magazine]
English, Scientific journal, INTRODUCTION: Liver transplantation (LT) indications for hepatocellular carcinoma (HCC) have broadened, increasing the need for systemic therapy in post-transplant recurrence. Because of the risks of graft rejection and uncertain efficacy, immunotherapy remains controversial, making tyrosine kinase inhibitors (TKIs) such as lenvatinib and sorafenib the preferred first-line treatments. However, their comparative efficacy in this setting remains unclear, warranting further research. METHODS: We conducted a retrospective, multicenter study of HCC recurrence after LT treated with either lenvatinib or sorafenib as first-line systemic treatment. Primary objectives were to compare overall survival (OS), progression-free survival (PFS) and treatment response assessed per RECIST 1.1. A meta-analysis incorporating prior studies was carried out to enhance the robustness of findings. Safety was evaluated as the rate of adverse events onset graded as per CTCAE v5.0. RESULTS: In a cohort of 64 patients (lenvatinib: 40, sorafenib: 24), lenvatinib significantly improved median OS (19.5 vs. 11.4 months, HR 0.31, p = 0.003), as confirmed in a meta-analysis with another recent report (HR 0.43, p = 0.0012). Although PFS was longer with lenvatinib (7.3 vs. 4.6 months), the difference was not significant (HR 0.91, p = 0.73). Both treatments had comparable safety profiles, with lenvatinib linked to higher hypertension and proteinuria rates, and sorafenib associated with more hand-foot syndrome and diarrhea. CONCLUSIONS: This study provides real-world evidence that lenvatinib confers superior overall survival over sorafenib in recurrent HCC post-LT, with manageable toxicity. As LT indications expand, these findings support lenvatinib as a preferred first-line treatment. Further prospective studies are needed to confirm these results and optimize post-LT treatment strategies. - Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.
Takatsugu Tanaka; Goki Suda; Masatsugu Ohara; Osamu Maehara; Tomoka Yoda; Qingjie Fu; Zijian Yang; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Shunsuke Ohnishi; Naoya Sakamoto
Frontiers in nutrition, 13, 1730695, 1730695, 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Cachexia is associated with poor prognosis in chronic liver disease (CLD), yet robust predictors remain poorly defined. This study examined clinical factors and serum biomarkers associated with cachexia in patients with CLD. METHODS: We analyzed 356 of 526 patients with CLD who had complete cachexia assessment and available stored serum samples. In a discovery cohort (n = 240; Aug 2014-Jun 2023), serum fibroblast growth factor 21 (FGF21), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. Multivariable logistic regression and receiver operating characteristic analyses were used to identify independent predictors and optimal cutoff values. Findings were subsequently evaluated in an independent validation cohort (n = 116; Jul 2023-May 2025). RESULTS: Median age was 68 years (range 19-90), 65.8% of participants were male, and 24.6% had cachexia, which independently predicted worse overall survival (hazard ratio 1.64; 95% CI 1.03-2.62; p = 0.038). Patients with cachexia had higher serum FGF21 concentrations than those without cachexia (median, 292 vs. 177 pg./mL; p = 0.002), whereas IL-6 and TNF-α levels did not differ significantly between groups. FGF21 was the only biomarker independently associated with cachexia (odds ratio, 1.71; 95% CI, 1.10-2.66; p = 0.016). Advanced Child-Pugh class and platelet count were identified as additional independent clinical predictors. CONCLUSION: Serum FGF21 independently predicts cachexia in CLD and may facilitate earlier identification of at-risk patients, enabling timely intervention to improve clinical outcomes. - Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
Goki Suda; Masaru Baba; Yoshiya Yamamoto; Sonoe Yoshida; Tetsuhito Muranaka; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Takaaki Izumi; Tomofumi Takagi; Shunichi Hosoda; Ren Yamada; Qingjie Fu; Zijian Yang; Daisuke Yokoyama; Takatsugu Tanaka; Akimitsu Meno; Naohiro Yasuura; Takashi Kitagataya; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
Scientific reports, 15, 1, 42628, 42628, 28 Nov. 2025, [International Magazine]
English, Scientific journal, Simplified ("minimal monitoring") pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and effectively with fewer visits remains unclear, and real-world outcomes with sofosbuvir/velpatasvir are scarce. We evaluated effectiveness, safety, and visit frequency in a multicenter cohort. Sixty patients with HCV-infection, with or without compensated liver cirrhosis, received 12 weeks of sofosbuvir/velpatasvir with follow-up to sustained virologic response at 12 weeks post-treatment (SVR12). The visit number was set with no schedule and analyzed post hoc (≤ 3 vs. ≥4 visits). There were 1-8 outpatient visits (median 3). SVR12 was 96.7% by intention-to-treat (ITT; 58/60; 95% CI, 88.6-99.6) and 100% per protocol (57/57; 95% CI, 90.0-100.0). Cure rates were comparable (ITT 95.8-97.2% for ≤ 3 vs. ≥4 visits; p = 1.00; PP 100% in both). Sofosbuvir/velpatasvir was well-tolerated: adverse events were recorded in 10%, none grade ≥ 3, no treatment-related serious events, and no toxicity-related discontinuations. Two patients were lost to follow-up; one who discontinued treatment achieved SVR12. This is the first Japanese real-world evaluation of DAA under simplified monitoring and supports low-burden pathways with high efficacy and safety. - Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.
Takashi Kitagataya; Goki Suda; Takatsugu Tanaka; Shoichi Kitano; Naohiro Yasuura; Akimitsu Meno; Takashi Sasaki; Risako Kohya; Qingjie Fu; Shunichi Hosoda; Sonoe Yoshida; Osamu Maehara; Shunsuke Ohnishi; Masatsugu Ohara; Masato Nakai; Takuya Sho; Kosuke Nakamura; Suguru Ishizaka; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 55, 10, 1367, 1375, Oct. 2025, [International Magazine]
English, Scientific journal, AIM: Cirrhotic cardiomyopathy (CCM) is a significant complication of liver cirrhosis; however, its prevalence and impact in Asian populations remain unclear. The aim of this study was to assess the prevalence of CCM in Japanese patients with liver cirrhosis and to evaluate its impact on clinical outcomes. METHODS: In this retrospective study, 80 patients with liver cirrhosis confirmed using transient elastography (liver stiffness ≥ 12.5 kPa) were included. Study was performed at Hokkaido University Hospital between January 2014 and April 2024. CCM was diagnosed using the 2019 Cirrhotic Cardiomyopathy Consortium criteria. Subsequently, patient characteristics, survival, and the incidences of decompensation and cardiovascular events were analyzed. RESULTS: The prevalence of CCM was 46.3% (37/80), with 78.4% of patients with CCM showing isolated systolic dysfunction based on global longitudinal strain. Patients with CCM were significantly older, had lower serum ammonia and bilirubin levels, and had higher platelet counts. CCM was associated with a significantly higher incidence of decompensation events (hazard ratio 3.97, 95% confidence interval 1.64-9.61, p = 0.003) and was an independent risk factor for decompensation in the multivariate analysis (hazard ratio 3.24, 95% confidence interval 1.29-8.11, p = 0.012). Patients with and without CCM showed no significant differences in overall survival or cardiovascular events. CONCLUSIONS: CCM is prevalent among Japanese patients with liver cirrhosis and is associated with an increased risk of hepatic decompensation. These findings highlight the importance of cardiac evaluation in patients with cirrhosis and suggest that CCM should be considered in the management of liver cirrhosis to improve patient outcomes. - Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.
Goki Suda; Masaya Sugiyama; Hayato Hikita; Akira Nishio; Tomohide Tatsumi; Tetsuo Takehara; Miyako Murakawa; Mina Nakagawa; Yasuhiro Asahina; Masashi Mizokami; Tatsuhiko Kakisaka; Yuzuru Sakamoto; Akinobu Taketomi; Koji Miyanishi; Yoshiyuki Ueno; Hiroaki Haga; Shinya Maekawa; Nobuyuki Enomoto; Masayuki Kurosaki; Motoyuki Kohjima; Makoto Nakamuta; Yasuhito Tanaka; Yoshiya Yamamoto; Masaru Baba; Hisatoshi Hanamatsu; Jun-Ichi Furukawa; Masatsugu Ohara; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto
Biomarker research, 13, 1, 113, 113, 24 Sep. 2025, [International Magazine]
English, A subset of patients still develops hepatocellular carcinoma (HCC) even after eradication of the hepatitis-C virus (HCV) by anti-HCV treatment. We conducted a genome-wide association study (GWAS) to identify host genetic factors associated with HCC development following HCV eradication in Japan. In this GWAS (n = 517), the discovery cohort included 118 patients without HCC and 67 who developed HCC following HCV eradication with interferon-based therapy. A genome-wide scan for HCC-associated variants was conducted. An independent cohort of 274 patients without HCC and 58 patients with post-eradication HCC was used for replication. The effects of candidate gene variants were assessed clinically and through in vitro cellular assays. The GWAS identified significant variants associated with HCC development following HCV eradication, including rs4778350, located near the long non-coding RNA Prader-Willi non-protein coding RNA 4 (PWRN4) on chromosome 15. In the combined analysis, rs4778350 remained significantly associated with HCC, showing a high odds ratio of 5.86 (95% CI, 3.63-9.44). The frequency of the A allele in rs4778350 differs across ethnic populations. Multivariate analysis revealed that female sex, high platelet count, and higher serum albumin levels were associated with reduced HCC risk, while fibrosis stage F4 and the AA genotype of rs4778350 were linked to increased risk. The AA genotype of rs4778350 enhanced PWRN4 expression, promoting cell proliferation, migration, and invasion. These findings suggest a role for PWRN4 in hepatocarcinogenesis through its association with rs4778350 in patients achieving HCV eradication. - 切除不能進行肝細胞に対するアテゾリズマブ+ベバシズマブ治療と局所療法併用のインパクト
荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 坂本 直哉
肝臓, 66, Suppl.2, A640, A640, (一社)日本肝臓学会, Sep. 2025
Japanese - Bacterial translocationマーカーによる腹水を有する非代償性肝硬変の利尿剤反応性と予後予測
中井 正人; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
肝臓, 66, Suppl.2, A658, A658, (一社)日本肝臓学会, Sep. 2025
Japanese - 慢性肝疾患におけるTPORAの有効性の検討 脾臓体積に注目して
中井 正人; 横山 大輔; 田中 崇倫; 北野 翔一; 保浦 直弘; 目野 晃光; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
日本門脈圧亢進症学会雑誌, 31, 3, 161, 161, (一社)日本門脈圧亢進症学会, Aug. 2025
Japanese - Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Risako Kohya; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Takuya Sho; Makoto Chuma; Atsumasa Komori; Yuki Kugiyama; Yutaka Yasui; Kaoru Tsuchiya; Masayuki Kurosaki; Joji Tani; Shun Kaneko; Mina Nakagawa; Yasuhiro Asahina; Shinya Maekawa; Nobuyuki Enomoto; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
JHEP reports : innovation in hepatology, 7, 5, 101364, 101364, May 2025, [International Magazine]
English, Scientific journal, BACKGROUND & AIMS: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment response in patients with hepatocellular carcinoma (HCC) treated with immune-checkpoint inhibitors (ICIs) remain unclear. Thus, this study investigated the potential of high FGF21 levels as a prognostic marker and whether traditional ICI-based therapy can improve the prognosis of patients with high FGF21 levels. METHODS: In this retrospective multicentre study, patients with unresectable HCC who received atezolizumab/bevacizumab in the NORTE study group (n = 117) were classified into high (≥915 pg/ml; n = 29) and non-high (n = 88) FGF21 groups. For validation, we investigated patients treated with atezolizumab/bevacizumab in an independent cohort (n = 285). Overall survival, progression-free survival, and treatment response were compared between patients with and without high baseline FGF21 levels. RESULTS: The median overall survival (p <0.001) and progression-free survival (p = 0.045) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. Independent cohort analysis validated these results. In the overall cohort, the median progression-free survival (5.75 vs. 8.84 months; p = 0.027) and median overall survival (14.13 vs. 22.08 months; p <0.001) were significantly shorter in the high FGF21 group than in the non-high FGF21 group. The durable response (≥6 months) + complete response rate was significantly decreased in the high FGF21 group (p = 0.045). No patient with a high FGF21 level achieved a complete response, whereas this was achieved in 4.1% (13/319) of patients with non-high FGF21 levels. Multivariate Cox regression analysis identified high baseline serum FGF21 as an independent poor prognostic factor for overall survival (hazard ratio 2.20, p <0.001). CONCLUSIONS: Serum FGF21 may be a robust, non-invasive prognostic and treatment response marker for unresectable HCC treated with atezolizumab/bevacizumab. IMPACT AND IMPLICATIONS: FGF21 has been reported to act as a secreted immune-checkpoint factor, and elevated levels of FGF21 are associated with a poor prognosis in patients with HCC. It is not fully understood whether ICIs can overcome the impact of high FGF21 levels on the shortened prognosis of patients with HCC. In this multicentre retrospective study, patients with HCC and high baseline levels of serum FGF21 who received atezolizumab/bevacizumab treatment exhibited a significantly shorter overall survival and shorter progression-free survival. These findings suggest serum FGF21 as a robust prognostic marker and an indicator of treatment response in unresectable HCC treated with ICI-based therapy. These findings could be crucial for the implementation of personalised treatment strategies for unresectable HCC. However, identifying optimal therapeutic options for patients with unresectable HCC and high serum FGF21 levels remains an urgent and critical clinical issue. - Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
Hisatoshi Hanamatsu; Goki Suda; Masatsugu Ohara; Koji Ogawa; Nobuharu Tamaki; Hayato Hikita; Hiroaki Haga; Shinya Maekawa; Masaya Sugiyama; Tatsuhiko Kakisaka; Masato Nakai; Takuya Sho; Nobuaki Miura; Masayuki Kurosaki; Yasuhiro Asahina; Akinobu Taketomi; Yoshiyuki Ueno; Tetsuo Takehara; Takashi Nishikaze; Jun-Ichi Furukawa; Naoya Sakamoto
Journal of gastroenterology, 60, 4, 456, 468, Apr. 2025, [Domestic magazines]
English, Scientific journal, BACKGROUND: Advanced liver fibrosis in cases of metabolic dysfunction-associated steatotic liver disease (MASLD) leads to cirrhosis and hepatocellular carcinoma. The current gold standard for liver fibrosis is invasive liver biopsy. Therefore, a less invasive biomarker that accurately reflects the stage of liver fibrosis is highly desirable. METHODS: This study enrolled 269 patients with liver biopsy-proven MASLD. Patients were divided into three groups (F0/1 (n = 41/85), F2 (n = 47), and F3/4 (n = 72/24)) according to fibrosis stage. We performed serum N-glycomics and identified glycan biomarker for fibrosis stage. Moreover, we explored the carrier proteins and developed a sandwich ELISA to measure N-glycosylation changes of carrier protein. RESULTS: Comprehensive N-glycomic analysis revealed significant changes in the expression of A2F bisect and its precursors as fibrosis progressed. The sum of neutral N-glycans carrying bisecting GlcNAc and core Fuc (neutral sum) had a better diagnostic performance to evaluate advanced liver fibrosis (AUC = 0.804) than conventional parameters (FIB4 index, aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), and serum level of Mac-2-binding protein glycol isomer (M2BPGi). The combination of the neutral sum and FIB4 index enhanced diagnostic performance (AUC = 0.840). IgM, IgA, and complement C3 were identified as carrier proteins with A2F bisect N-glycan. A sandwich ELISA based on N-glycans carrying bisecting GlcNAc and IgA showed similar diagnostic performance than the neutral sum. CONCLUSIONS: A2F bisect N-glycan and its precursors are promising candidate biomarkers for advanced fibrosis in MASLD patients. Analysis of these glycan alterations on IgA may have the potential to serve as a novel ELISA diagnostic tool for MASLD in routine clinical practice. CLINICAL TRIAL NUMBER: UMIN000030720. - 肝内胆管癌との鑑別に難渋し手術加療にて診断が得られた肝偽リンパ腫の1例
田中 崇倫; 北潟谷 隆; 北野 翔一; 目野 晃光; 保浦 直弘; 佐々木 貴志; 甲谷 理紗子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 柿坂 達彦; 種井 善一; 田中 伸哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 136回・130回, 65, 65, 日本消化器病学会-北海道支部, Mar. 2025
Japanese - 肝線維化・肝発癌における基礎と臨床の融合 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
大原 正嗣; 須田 剛生; 保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 北潟谷 隆; 中井 正人; 荘 拓也; 坂本 直哉
日本消化器病学会雑誌, 122, 臨増総会, A212, A212, (一財)日本消化器病学会, Mar. 2025
Japanese - Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Zijian Yang; Goki Suda; Takuya Sho; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Qingjie Fu; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Yoshiya Yamamoto; Masaru Baba; Ren Yamada; Tomoe Kobayashi; Minhu Chen; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 25 Nov. 2024, [International Magazine]
English, Scientific journal, AIM: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear. We aimed to clarify these. METHODS: In this multicenter retrospective study, we screened patients with HCC treated with atezolizumab/bevacizumab. The prognostic impact of grade ≥2 proteinuria was examined in patients with proper clinical data and preserved serum for growth factor analysis. For biomarker analysis predicting proteinuria, baseline serum vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D levels were analyzed. RESULTS: This study included 75 patients, and 32 (42.7%) experienced grade ≥2 proteinuria. No significant differences were observed between those with or without proteinuria, except for aspartate transaminase and alanine transaminase levels. Time-dependent Cox proportional hazards analysis revealed that grade ≥2 proteinuria was significantly associated with better prognosis (hazard ratio 0.221; 95% confidence interval 0.082-0.592; p = 0.003). In biomarker analysis, low baseline serum VEGF-C and VEGF-D levels were significantly associated with proteinuria, and multivariate analysis demonstrated that baseline serum VEGF-D level was significantly associated with grade ≥2 proteinuria (hazard ratio 0.101; 95% confidence interval 0.029-0.357; p < 0.001). CONCLUSIONS: Grade ≥2 proteinuria in patients with unresectable HCC treated with atezolizumab/bevacizumab indicates a better prognosis, and baseline serum VEGF-D levels can help predict its occurrence. These findings can help in managing adverse events and prognosis in advanced HCC treated with atezolizumab/bevacizumab. - Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study.
Mara Persano; Andrea Casadei-Gardini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Federico Rossari; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Alberto Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Mariangela Bruccoleri; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Luigi Mascia; Silvia Foti; Silvia Camera; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Margherita Rimini
Oncology, 1, 27, 11 Oct. 2024, [International Magazine]
English, Scientific journal, INTRODUCTION: the most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC. This real-world study aims to compare outcomes reached by lenvatinib and sorafenib second-line therapy in this setting. METHODS: the overall cohort included 891 patients with HCC from 5 countries treated with atezolizumab plus bevacizumab in first-line setting between October 2018 and April 2022. At data cut-off (May 2022), 41.5% of patients were continuing first-line treatment, 5.5% were lost at follow up, and 53.0% of patients had progressive disease after first-line therapy. 51.5% of patients with progressive disease received a second-line treatment, while 48.5% didn't receive any subsequent therapy. Between patients receiving second-line treatment, 11.1% patients underwent transarterial chemoembolization, 21.0% received sorafenib, 35.4% underwent lenvatinib, and 32.5% were treated with other drugs. RESULTS: lenvatinib second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; HR: 2.24) compared to sorafenib subgroup that reached a mOS of 14.3 months. The multivariate analysis highlighted Albumin-Bilirubin 1 grade [p < 0.01; hazard ratio (HR): 5.23] and lenvatinib second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factors for OS. The forest plot highlighted a positive trend in terms of OS in favor of patients treated with lenvatinib second-line regardless of baseline characteristics before first-line therapy. CONCLUSION: these results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib. - 進行肝細胞癌の薬物治療 切除不能進行肝細胞癌におけるアテゾリズマブ+ベバシズマブ併用療法後のICI-Rechallenge療法の治療効果と安全性の検討
馬場 英; 荘 拓也; 坂本 直哉
肝臓, 65, Suppl.3, A773, A773, (一社)日本肝臓学会, Oct. 2024
Japanese - 進行肝細胞癌治療の到達点と将来展望 切除不能進行肝細胞に対するアテゾリズマブ+ベバシズマブ治療の治療成績とLocoregional治療併用への期待
荘 拓也; 須田 剛生; 坂本 直哉
日本消化器病学会雑誌, 121, 臨増大会, A574, A574, (一財)日本消化器病学会, Oct. 2024
Japanese - 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
甲谷 理紗子; 須田 剛生; 大原 正嗣; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉
日本消化器病学会雑誌, 121, 臨増大会, A802, A802, (一財)日本消化器病学会, Oct. 2024
Japanese - Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.
Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Silvia Camera; Bernardo Stefanini; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
Liver cancer, 13, 5, 522, 536, Oct. 2024, [Peer-reviewed], [International Magazine]
English, Scientific journal, INTRODUCTION: The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD-1/PD-L1 blockers. As a results, it is not clear whether the first-line systemic treatment atezolizumab plus bevacizumab (A + B) is equally effective in viral and nonviral patients. METHODS: We retrospectively analyzed 885 HCC patients treated with the first-line A + B from multiple centers from Eastern and Western countries, 53.9% having viral and 46.1% nonviral etiology. Baseline clinical and laboratory characteristics were analyzed with uni- and multivariate models to explore potential differences on overall survival (OS), time-to-progression (TTP), disease control rates (DCRs) based on etiology and to identify putative prognostic factors in etiology subgroups. Treatment toxicities and access to the second-line treatments and outcomes were also reported and compared between etiologies. RESULTS: Overall, no statistically significant differences were found in median OS (mOS: viral 15.9 months; nonviral 16.3 months), TTP (mTTP: viral 8.3 months; nonviral 7.2 months), and DCRs (viral 78.1%; nonviral 80.8%) based on etiology. Prognostic factors of survival and progression were mainly shared between viral and nonviral etiologies, including alpha-fetoprotein, aspartate transaminase, neutrophil-to-lymphocyte ratio (NLR) and ALBI score. Exploratory analyses highlighted a possible stronger association of immunological factors, i.e., NLR and eosinophil count, to treatment outcomes in viral patients. The toxicity profile, the access to and type of the second-line treatments and their outcome in terms of OS almost overlap in the two etiology subgroups. CONCLUSION: Atezolizumab plus bevacizumab efficacy does not vary according to underlying etiology of HCC in a multicenter, real-world population, matching recent post hoc findings from the IMbrave-150 trial. Preliminary analyses suggest that some prognostic factors differ between viral and nonviral patients, potentially due to biological and immunological differences. Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice. - Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Naohiro Yasuura; Goki Suda; Masatsugu Ohara; Akimitsu Meno; Takuya Sho; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Tomoya Saitou; Masaya Sugiyama; Takasuke Fukuhara; Masaru Baba; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Mitsuteru Natsuizaka; Koji Ogawa; Akinobu Taketomi; Naoya Sakamoto
Alimentary pharmacology & therapeutics, 04 Sep. 2024, [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps. METHODS: We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC. RESULTS: A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC. CONCLUSIONS: In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis. - Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Takuya Sho; Goki Suda; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Sonoe Yoshida; Shunichi Hosoda; Koji Ogawa; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Masaru Baba; Yoshiya Yamamoto; Yoko Tsukuda; Takashi Meguro; Ren Yamada; Tomoe Kobayashi; Tomofumi Takagi; Naoya Sakamoto
Targeted oncology, 19, 5, 769, 778, Sep. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: While guidelines recommend immune checkpoint inhibitor (ICI) rechallenge as second-line therapy for unresectable hepatocellular carcinoma (HCC), data supporting this remain limited, particularly regarding a standard regimen for first- and second-line treatments. Tremelimumab/durvalumab was recently approved but data on ICI rechallenge are lacking. OBJECTIVES: The purpose of this study was to evaluate the early efficacy and safety of tremelimumab/durvalumab for HCC as an ICI rechallenge following initial ICI therapy with atezolizumab/bevacizumab. PATIENTS AND METHODS: This multicenter retrospective study included patients with HCC who underwent treatment with tremelimumab/durvalumab, with relevant available clinical information. We evaluated the safety and efficacy of tremelimumab/durvalumab as ICI rechallenge following initial treatment with atezolizumab/bevacizumab. We analyzed the outcomes in patients who underwent tremelimumab/durvalumab as an ICI rechallenge and those who received tremelimumab/durvalumab as their initial ICI therapy RESULT: A total of 45 patients treated with tremelimumab/durvalumab were included, with 55.6% (25/45) undergoing ICI rechallenge. The objective-response and disease-control rates in patients who underwent ICI rechallenge were 14.3% (3/21) and 47.6% (10/21), respectively, similar to those in patients initially treated with tremelimumab/durvalumab. All patients (n = 3) who experienced the best response to progressive disease (PD) with initial atezolizumab/bevacizumab experienced PD during ICI rechallenge. The incidence rates of adverse events were similar between patient groups treated with tremelimumab/durvalumab as ICI rechallenge and initial ICI. Among patients experiencing immune-related adverse events (irAEs) with atezolizumab/bevacizumab, 75% (3/4) encountered similar irAEs during ICI rechallenge. CONCLUSION: Early safety and efficacy profiles of durvalumab/tremelimumab as ICI rechallenge are satisfactory. - 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信
肝臓, 65, 5, 249, 249, (一社)日本肝臓学会, May 2024
Japanese - 末梢血幹細胞移植前後で発症し,再活性化が疑われた急性E型肝炎の1例
久保 彰則; 小川 浩司; 得地 祐匡; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉
肝臓, 65, 5, 259, 259, (一社)日本肝臓学会, May 2024
Japanese - 急性肝不全に対する移植スコアリングシステム High-flow hemodiafiltration時代の急性肝不全診療
川村 典生; 嶋村 剛; 後藤 了一; 巖築 慶一; 渡辺 正明; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 武冨 紹信
肝臓, 65, 5, 249, 249, (一社)日本肝臓学会, May 2024
Japanese - 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信
日本外科学会定期学術集会抄録集, 124回, RS, 3, (一社)日本外科学会, Apr. 2024
Japanese - 当院において経皮経脾静脈アプローチによるIVRを施行した2例
高柳 歩; 阿保 大介; 森田 亮; 高橋 文也; 木野田 直也; 加藤 大祐; 藤井 宝顕; 山崎 康之; 中西 喜嗣; 荘 拓也; 中井 正人; 平野 聡; 工藤 與亮
日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 304, 304, (一社)日本インターベンショナルラジオロジー学会, Apr. 2024
Japanese - 消化器癌における薬物療法の超音波検査による治療効果判定 LEN-TACE療法の治療効果判定における造影USの役割
荘 拓也; 北潟谷 隆; 大原 正嗣; 中井 正人; 須田 剛生; 坂本 直哉
超音波医学, 51, Suppl., S200, S200, (公社)日本超音波医学会, Apr. 2024
Japanese - 当院において経皮経脾静脈アプローチによるIVRを施行した2例
高柳 歩; 阿保 大介; 森田 亮; 高橋 文也; 木野田 直也; 加藤 大祐; 藤井 宝顕; 山崎 康之; 中西 喜嗣; 荘 拓也; 中井 正人; 平野 聡; 工藤 與亮
日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 304, 304, (一社)日本インターベンショナルラジオロジー学会, Apr. 2024
Japanese - 昏睡型亜急性型急性肝不全に対し,保存的加療または肝移植にて救命しえた2例
松井 双葉; 後藤 了一; 川村 典生; 渡辺 正明; 金沢 亮; 津坂 隼也; 松居 剛志; 中井 正人; 荘 拓也; 小川 浩司; 嶋村 剛; 武冨 紹信
日本外科学会定期学術集会抄録集, 124回, RS, 3, (一社)日本外科学会, Apr. 2024
Japanese - 肝内胆管癌との鑑別に難渋した大腸癌遅発性肝転移再発の1例
目野 晃光; 小川 浩司; 保浦 直弘; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 折茂 達也; 柿坂 達彦
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 47, 47, 日本消化器病学会-北海道支部, Mar. 2024
Japanese - 非代償性肝硬変の課題克服を目指して 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
中井 正人; 大原 正嗣; 北潟谷 隆; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
日本消化器病学会雑誌, 121, 臨増総会, A158, A158, (一財)日本消化器病学会, Mar. 2024
Japanese - 食道胃静脈瘤に対し経皮経脾静脈瘤塞栓術を施行した1例
保浦 直弘; 大原 正嗣; めの 晃光; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 阿保 大介; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 46, 46, 日本消化器病学会-北海道支部, Mar. 2024
Japanese - Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Silvia Camera; Margherita Rimini; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Francesca Salani; Mariarosaria Marseglia; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Sara Lonardi; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Targeted oncology, 19, 1, 29, 39, 22 Jan. 2024, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing. OBJECTIVE: This analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC. PATIENTS AND METHODS: The study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022. Patients were stratified according to age as very old (≥ 80 years) and not very old (< 80 years). RESULTS: The median overall survival (OS) was 15.7 months for patients < 80 years old and 18.4 months for patients ≥ 80 years old [hazard ratio (HR) = 1.02, 95% confidence interval (CI) 0.84-1.25, p = 0.8281]. Median progression free survival (PFS) was 6.3 months for patients < 80 years old and 6.5 months for patients ≥ 80 years old (HR = 1.07, 95% CI 0.91-1.25, p = 0.3954). No differences between the two study groups were found in terms of disease control rate (DCR; 80.8% versus 78.8%; p = 0.44) and response rate (RR; 38.2% versus 37.9%; p = 0.88). Patients < 80 years old experienced significantly more hand-foot skin reaction (HFSR) grade ≥ 2 and decreased appetite grade ≥ 2. Conversely, patients ≥ 80 years old experienced significantly more fatigue grade ≥ 2. In the very old group, parameters associated with prognosis were AFP, albumin-bilirubin (ALBI) grade, Barcelona Clinic Liver Cancer (BCLC), and Child-Pugh score. BCLC stage was the only independent predictor of overall survival (OS; HR = 1.59, 95% CI 1.11-2.29, p = 0.01115). CONCLUSIONS: Our study highlights the same efficacy and safety of lenvatinib between very old and not very old patients. - IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討 多施設共同研究
荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉
日本消化器病学会雑誌, 120, 臨増大会, A813, A813, (一財)日本消化器病学会, Oct. 2023
Japanese - 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈
荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉
肝胆膵, 87, 4, 439, 446, (株)アークメディア, Oct. 2023
Japanese - IMbrave150基準外進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉
肝胆膵, 87, 4, 508, 509, (株)アークメディア, Oct. 2023
Japanese - 北海道における肝炎医療コーディネーター養成研修会の実施状況の変遷に関する検討
大原 正嗣; 小川 浩司; 長谷川 智子; 櫻井 菜々子; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
肝臓, 64, Suppl.3, A808, A808, (一社)日本肝臓学会, Oct. 2023
Japanese - IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討 多施設共同研究
荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉
日本消化器病学会雑誌, 120, 臨増大会, A813, A813, (一財)日本消化器病学会, Oct. 2023
Japanese - 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 Phase 3 HIMALAYA試験の結果とその解釈
荘 拓也; 須田 剛生; 北潟谷 隆; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉
肝胆膵, 87, 4, 439, 446, (株)アークメディア, Oct. 2023
Japanese - IMbrave150基準外進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
荘 拓也; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 出水 孝章; 目黒 高志; 中村 晃久; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 坂本 直哉
肝胆膵, 87, 4, 508, 509, (株)アークメディア, Oct. 2023
Japanese - 肝肺症候群を合併したBudd-Chiari症候群の1例
保浦 直弘; 目野 晃光; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 40, 40, 日本消化器病学会-北海道支部, Sep. 2023
Japanese - 腹腔鏡下横隔膜縫合術、腹腔静脈シャント術により体液コントロールされた肝硬変の1例
目野 晃光; 小川 浩司; 保浦 直弘; 甲谷 理紗子; 佐々木 貴志; 細田 峻一; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉; 武藤 潤
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 40, 40, 日本消化器病学会-北海道支部, Sep. 2023
Japanese - 肝癌患者におけるマニュアルトレース法による筋肉量と皮下脂肪CT値評価の有用性の検討
大原 正嗣; 須田 剛生; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉
肝臓, 64, Suppl.2, A644, A644, (一社)日本肝臓学会, Sep. 2023
Japanese - Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
Masato Nakai; Kenichi Morikawa; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
Journal of gastroenterology, 58, 7, 656, 667, Jul. 2023, [Domestic magazines]
English, Scientific journal, BACKGROUND: Acute kidney injury (AKI) is associated with liver cirrhosis (LC), water retention, diuretics to treat water retention, and a poor prognosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) reportedly predicts a poor prognosis in decompensated LC. This study investigated the usefulness of uNGAL in predicting the short- and long-term effects of tolvaptan (TVP) and the incidence of AKI post-TVP administration. METHODS: Of the LC cases with water retention, 86 with available pre-treatment uNGAL were analyzed. A short-term response was defined as weight loss of ≥ 1.5 kg within the first week; a long-term response was defined as a short-term response without early recurrence. The uNGAL usefulness in predicting the short- and long-term effects of TVP and AKI incidence post-TVP administration was investigated. RESULTS: Short-term effects of TVP were observed in 52 patients. Of these, 15 patients had an early recurrence. In multivariate analysis, significant short-term predictive factors were C-reactive protein (CRP) < 1.4 mg/dl, uNa/K ratio ≥ 3.51, and uNGAL < 50.2 ng/ml. Patients were classified according to these three cut-off values, with short-term response rates of 92.9%, 68.8%, 26.7%, and 0% for 0, 1, 2, and 3 points, respectively. CRP < 0.94 mg/dl and uNGAL < 50.2 ng/ml were significant factors for predicting the long-term response of TVP. The AKI incidence post-TVP was 8.1% (n = 7) and was significantly higher among those with uNGAL ≥ 38.1 ng/mL. CONCLUSION: uNGAL is a useful predictor of the short- and long-term efficacy of TVP and can be useful in predicting AKI incidence post-TVP administration. - Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
Risako Kohya; Goki Suda; Masatsugu Ohara; Takashi Sasaki; Tomoka Yoda; Naofumi Sakurai; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Cancers, 15, 12, 20 Jun. 2023, [International Magazine]
English, Scientific journal, Lenvatinib, used for unresectable hepatocellular carcinoma (HCC), causes appetite loss, but the underlying mechanisms, clinical impact, and predictive factors have been unclear. The endocrine factor FGF21 modulates appetite and is involved in cachexia. We evaluated the association between FGF21 level changes during lenvatinib treatment for unresectable HCC and appetite loss. Sixty-three eligible unresectable HCC patients who started lenvatinib treatment between 2018 and 2021 were included. We analyzed FGF21 levels at baseline; 1, 2, and 4 weeks after lenvatinib initiation, and before the onset of appetite loss. Grade ≥ 2 lenvatinib-induced appetite loss led to liver functional reserve deterioration at disease progression and a poor prognosis. Baseline characteristics and serum FGF21 levels were similar between patients with and without appetite loss. However, the serum FGF21 change rate increased significantly at 4 weeks post-lenvatinib initiation in patients with grade ≥ 2 appetite loss, as compared to those without appetite loss. Similar significant increases in the serum FGF21 level change rate were observed prior to grade ≥ 2 appetite loss onset. This suggests that changes in FGF21 levels can be used to predict patients with a greater risk of marked appetite loss and provides insights into the mechanisms underlying lenvatinib-induced appetite loss in patients with HCC. - Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Takashi Sasaki; Goki Suda; Masatsugu Ohara; Shunichi Hosoda; Naoki Kawagishi; Risako Kohya; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Sho Komukai; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 18 Jun. 2023, [International Magazine]
English, Scientific journal, AIM: Although hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in many countries. In Japan, HDV prevalence has not been updated for over 20 years. We aimed to investigate the recent prevalence of HDV infections in Japan. METHODS: We screened 1264 consecutive patients with HBV infection at Hokkaido University Hospital between 2006 and 2022. Patients' serums were preserved and subsequently tested for HDV antibody (immunoglobulin-G). Available clinical information was collected and analyzed. We compared the changes in liver fibrosis using the Fibrosis-4 (FIB-4) index between propensity-matched patients with and without the evidence of anti-HDV antibodies and corrected for baseline FIB-4 index, nucleoside/nucleotide analog treatment, alcohol intake, sex, HIV coinfection, liver cirrhosis, and age. RESULTS: After excluding patients without properly stored serums and those lacking appropriate clinical information, 601 patients with HBV were included. Of these, 1.7% of patients had detectable anti-HDV antibodies. Patients with anti-HDV antibody serum positivity had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV coinfection than those who demonstrated serum anti-HDV antibody negativity. A propensity-matched longitudinal analysis revealed that liver fibrosis (FIB-4 index) progressed more rapidly in patients with positive results for anti-HDV antibody tests. CONCLUSIONS: The recent prevalence of HDV infections in Japanese patients with HBV was 1.7% (10/601). These patients experienced rapid liver fibrosis progression, highlighting the importance of routine HDV testing. - Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Shunichi Hosoda; Goki Suda; Takuya Sho; Koji Ogawa; Megumi Kimura; Zijian Yang; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
Liver cancer, 12, 2, 156, 170, Jun. 2023, [International Magazine]
English, Scientific journal, INTRODUCTION: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. METHODS: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, 6 weeks after treatment initiation (early PD; n = 13). Of these, 4 patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. RESULTS: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (<333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs. 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. CONCLUSION: Baseline low serum CXCL9 (<333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab. - 肝癌における薬物療法の最前線 Mbrave150基準外症例に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
荘 拓也; 須田 剛生; 坂本 直哉
肝臓, 64, Suppl.1, A159, A159, (一社)日本肝臓学会, Apr. 2023
Japanese - 肝硬変の成因と病態の推移 当科における肝硬変の成因分析
小川 浩司; 甲谷 理紗子; 佐々木 貴志; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
肝臓, 64, Suppl.1, A237, A237, (一社)日本肝臓学会, Apr. 2023
Japanese - Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Francesca Salani; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Marta Schirripa; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal of cancer research and clinical oncology, 149, 10, 7565, 7577, 28 Mar. 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, INTRODUCTION: The best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large sample of patients with unresectable HCC with CP B treated with atezolizumab plus bevacizumab Vs Lenvatinib. METHODS: The study population included patients affected by advanced (BCLC-C) or intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from both the Western and Eastern world (Italy, Germany, Republic of Korea and Japan), who received atezolizumab plus bevacizumab or Lenvatinib as first-line treatment. All the study population presented a CP class of B. The primary endpoint of the study was the overall survival (OS) of CP B patients treated with Lenvatinib compared to atezolizumab plus bevacizumab. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analyzed with log-rank tests. Finally, an interaction test was performed for the main baseline clinical characteristics. RESULTS: 217 CP B HCC patients were enrolled in the study: 65 (30%) received atezolizumab plus bevacizumab, and 152 (70%) received lenvatinib. The mOS for patients receiving Lenvatinib was 13.8 months (95% CI: 11.6-16.0), compared to 8.2 months (95% CI 6.3-10.2) for patients receiving atezolizumab plus bevacizumab as first-line treatment (atezolizumab plus bevacizumab Vs Lenvatinib: HR 1.9, 95% CI 1.2-3.0, p = 0.0050). No statistically significant differences were highlighted in terms of mPFS. The multivariate analysis confirmed that patients receiving Lenvatinib as first-line treatment have a significantly longer OS compared to patients receiving atezolizumab plus bevacizumab (HR 2.01; 95% CI 1.29-3.25, p = 0.0023). By evaluating the cohort of patients who received atezolizumab plus bevacizumab, we found that Child B patients with ECOG PS 0, or BCLC B stage or ALBI grade 1 were those who had benefited from the treatment thus showing survival outcomes no significantly different compared to those receiving Lenvatinib. CONCLUSION: The present study suggests for the first time a major benefit from Lenvatinib compared to atezolizumab plus bevacizumab in a large cohort of patients with CP B class HCC. - Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Yoshimasa Tokuchi; Goki Suda; Naoki Kawagishi; Masatsugu Ohara; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Osamu Maehara; Shunsuke Ohnishi; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Takashi Kitagataya; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 53, 7, 595, 606, 21 Mar. 2023, [International Magazine]
English, Scientific journal, AIM: Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct-acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long-term changes in the prevalence of fatty liver and hyper-low-density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs. METHODS: This retrospective study included patients with HCV who achieved sustained virologic response after interferon-free DAA and analyzed the changes in the prevalence of fatty liver diagnosed with controlled attenuation parameter (CAP), hyper-LDL cholesterolemia, and their relationships at baseline (n = 100) and 24 weeks (SVR24, n = 100), 96 weeks (SVR96, n = 100), and 144 weeks (SVR144, n = 90) after DAA. RESULTS: In 100 participants, the prevalence of fatty liver (19% vs. 32%, p = 0.0349) and hyper-LDL cholesterolemia (6% vs. 15%, p = 0.0379) significantly increased without changes in body weight at SVR96. Median total cholesterol, low-density lipoprotein cholesterol (LDL-C), and small-dense-LDL (sdLDL) levels and CAP values were significantly greater at SVR24, SVR96, and SVR144 than at baseline. Baseline CAP values and changes in CAP values were significantly negatively correlated at every observation point: r = -0.5305, p < 0.0001 at SVR24; r = -0.3617, p = 0.0005 at SVR96; and r = -0.4735, p < 0.0001 at SVR144. A similar relationship was observed in cholesterol levels. Unlike at baseline, CAP values were significantly positively correlated with LDL-C and sdLDL-C levels at all observation points after DAAs. CONCLUSIONS: Direct-acting antivirals may cause an increased prevalence of fatty liver accompanying hyper-LDL cholesterolemia without increased body weight. As post-SVR liver steatosis could cause HCC, careful follow-up may be required. - 肝細胞腺腫との鑑別が困難であった限局性結節性過形成の1例
吉田 苑永; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 細田 峻一; 久保 彰則; 得地 祐匡; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 42, 42, 日本消化器病学会-北海道支部, Mar. 2023
Japanese - BCLCステージB2肝癌に対してアテゾリズマブ+ベバシズマブ併用療法と焼灼療法にてCancer Freeが得られた1症例
細田 峻一; 荘 拓也; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 得地 祐匡; 大原 正嗣; 中井 正人; 須田 剛生; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 46, 46, 日本消化器病学会-北海道支部, Mar. 2023
Japanese - BavenoVI分類とYerdel分類を用いた肝疾患に伴う門脈血栓症に対するアンチトロンビンIII製剤の治療効果の検討
中井 正人; 小川 浩司; 佐々木 貴志; 甲谷 理紗子; 吉田 苑永; 細田 俊一; 得地 祐匡; 北潟谷 隆; 大原 正嗣; 荘 拓也; 須田 剛生; 坂本 直哉
日本消化器病学会雑誌, 120, 臨増総会, A417, A417, (一財)日本消化器病学会, Mar. 2023
Japanese - Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa Ramos; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Bernardo Stefanini; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Oncology, 101, 5, 283, 291, 19 Jan. 2023, [International Magazine]
English, Scientific journal, INTRODUCTION: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. METHODS: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). RESULTS: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p < 0.01) and progression-free survival (PFS) (8.7 vs. 5.8 months, HR 0.63, p < 0.01) compared to patients with low PNI. At the multivariate analysis, high versus low PNI resulted as an independent prognostic factor for OS (HR 0.49 , p < 0.01) and PFS (HR 0.82, p = 0.01). There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). CONCLUSION: PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab. - Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Tomoka Yoda; Takashi Sasaki; Risako Kohya; Sonoe Yoshida; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 15, 3, 18 Jan. 2023, [International Magazine]
English, Scientific journal, The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. - Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton.
Yusuke Uchinami; Norio Katoh; Daisuke Abo; Ryo Morita; Hiroshi Taguchi; Yoshihiro Fujita; Takahiro Kanehira; Ryusuke Suzuki; Naoki Miyamoto; Seishin Takao; Taeko Matsuura; Takuya Sho; Koji Ogawa; Tatsuya Orimo; Tatsuhiko Kakisaka; Keiji Kobashi; Hidefumi Aoyama
The British journal of radiology, 96, 1144, 20220720, 20220720, 12 Jan. 2023, [Peer-reviewed], [International Magazine]
English, Scientific journal, OBJECTIVES: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (one vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. METHODS: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. RESULTS: In 89 patients (XRT: 48, PBT: 41), those with two or three (2-3) predictive factors were higher normal liver doses than with zero or one (0-1) factor. In the PBT group, the ALBI score worsened more in patients with 2-3 factors than those with 0-1 factor, at 3 months (median 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. CONCLUSIONS: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. ADVANCES IN KNOWLEDGE: This study suggest that the number of predictive factors previously identified (0-1 vs 2-3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group. - Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Naoki Kawagishi; Goki Suda; Yoshiya Yamamoto; Masaru Baba; Ken Furuya; Osamu Maehara; Shunsuke Ohnishi; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Viruses, 15, 1, 07 Jan. 2023, [International Magazine]
English, Scientific journal, Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs. - Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Goki Suda; Masaru Baba; Yoshiya Yamamoto; Takuya Sho; Koji Ogawa; Megumi Kimura; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Qingjie Fu; Zijian Yang; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Tomoe Kobayashi; Izumi Tsunematsu; Naoya Sakamoto
Journal of medical virology, 95, 2, e28452, 04 Jan. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing HBV reactivation has yet been reported. METHODS: This multicenter prospective study enrolled HBV-carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV-reactivation and received TAF to prevent HBV reactivation-related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation-related hepatitis was evaluated at 6 and 12 months after initiating TAF. RESULTS: Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation-related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous-HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation-related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. CONCLUSION: TAF could effectively prevent HBV reactivation and HBV reactivation-related hepatitis. This article is protected by copyright. All rights reserved. - Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
Masatsugu Ohara; Goki Suda; Risako Kohya; Takashi Sasaki; Tomoka Yoda; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Osamu Maehara; Shunsuke Ohnishi; Yoshimasa Tokuchi; Takashi Kitagataya; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Frontiers in nutrition, 10, 1272728, 1272728, 2023, [International Magazine]
English, Scientific journal, INTRODUCTION: We aimed to assess the prognostic implications of muscle atrophy and high subcutaneous adipose tissue (SAT) radiodensity in patients with hepatocellular carcinoma (HCC). METHODS: In this retrospective study, muscle atrophy was assessed using the psoas muscle index (PMI) obtained from computed tomography. SAT radiodensity was evaluated based on radiodensity measurements. Survival and multivariate analyses were performed to identify factors associated with prognosis. The impact of muscle atrophy and high SAT radiodensity on prognosis was determined through survival analysis. RESULTS: A total of 201 patients (median age: 71 years; 76.6% male) with HCC were included. Liver cirrhosis was observed in 72.6% of patients, and the predominant Child-Pugh grade was A (77.1%). A total of 33.3% of patients exhibited muscle atrophy based on PMI values, whereas 12.9% had high SAT radiodensity. Kaplan-Meier survival analysis demonstrated that patients with muscle atrophy had significantly poorer prognosis than those without muscle atrophy. Patients with high SAT radiodensity had a significantly worse prognosis than those without it. Muscle atrophy, high SAT radiodensity, the Barcelona Clinic Liver Cancer class B, C, or D, and Child-Pugh score ≥ 6 were significantly associated with overall survival. Further classification of patients into four groups based on the presence or absence of muscle atrophy and high SAT radiodensity revealed that patients with both muscle atrophy and high SAT radiodensity had the poorest prognosis. CONCLUSION: Muscle atrophy and high SAT radiodensity are significantly associated with poor prognosis in patients with HCC. Identifying this high-risk subgroup may facilitate the implementation of targeted interventions, including nutritional therapy and exercise, to potentially improve clinical outcomes. - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Andrea Casadei-Gardini; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mara Persano; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Stefano Cascinu; Alessandro Cucchetti
European journal of cancer (Oxford, England : 1990), 180, 9, 20, 25 Nov. 2022, [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario. METHODS: Clinical features of lenvatinib and atezolizumab plus bevacizumab patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients' characteristics and measured outcomes of each patient in both treatment arms. Overall survival (OS) was the primary end-point. RESULTS: The analysis included 1341 patients who received lenvatinib, and 864 patients who received atezolizumab plus bevacizumab. After IPTW adjustment, atezolizumab plus bevacizumab did not show a survival advantage over lenvatinib HR 0.97 (p = 0.739). OS was prolonged by atezolizumab plus bevacizumab over lenvatinib in viral patients (HR: 0.76; p = 0.024). Conversely, OS was prolonged by lenvatinib in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (HR: 1.88; p = 0.014). In the IPTW-adjusted population, atezolizumab plus bevacizumab provided better safety profile for most of the recorded adverse events. CONCLUSION: Our study did not identify any meaningful difference in OS between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease might benefit more from lenvatinib therapy and patients with viral aetiology more from atezolizumab plus bevacizumab. - Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
Ren Yamada; Kenichi Morikawa; Kiyohiko Hotta; Daiki Iwami; Tatsu Tanabe; Sachiyo Murai; Nobuo Shinohara; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Megumi Kimura; Koji Yamamoto; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Journal of viral hepatitis, 29, 11, 976, 985, Nov. 2022, [International Magazine]
English, Scientific journal, Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current state of HBV markers after KT from donors with resolved HBV infection to HBV naïve recipients and the rate of HBV reactivation in recipients with resolved HBV infection. Furthermore, we investigated HBV covalently closed circular DNA (cccDNA) in transplanted organs from donors with resolved HBV infection and the capability of HBV replication in kidney cell lines. We retrospectively analysed the HBV status of 340 consecutive donors and recipients who underwent KT in a single centre. We prospectively measured cccDNA by real-time polymerase chain reaction in kidney biopsy specimens of 32 donors with resolved HBV infection. HBV reactivation was found in three recipients with resolved HBV infection (4.8%, 3/63) after KT. We analysed 45 cases of transplantation from donors with resolved HBV infection to HBV-naive recipients. One case (2.2%, 1/45) became seropositive for hepatitis B core antibody (anti-HBc) and in another case (2.2%, 1/45), HBV-DNA was detected qualitatively in an HBV naive recipient with a donor with resolved HBV infection. In the latter case, cccDNA was measured in the donor kidney during KT. HBV replication was observed in kidney cell lines with HBV plasmid transfection. In conclusion, the risk of reactivation in anti-HBc-positive donors is relatively low. However, post-transplant HBV monitoring should be conducted in all at-risk cases. - Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
Naoki Kawagishi; Goki Suda; Ryotaro Sakamori; Takeshi Matsui; Masahiro Onozawa; Zijian Yang; Sonoe Yoshida; Masatsugu Ohara; Megumi Kimura; Akinori Kubo; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Yoshimasa Tokuchi; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Hajime Sakai; Shunsuke Ohnishi; Masaru Baba; Tetsuo Takehara; Naoya Sakamoto
Scientific reports, 12, 1, 16800, 16800, 07 Oct. 2022, [Peer-reviewed], [International Magazine]
English, Scientific journal, De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1β levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94-333.3). HCV-infected patients with the IL-1β gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1β levels; no HCV-infected patient with the IL-1β AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1β levels. Low IL-1β levels were not associated with HBV reactivation. IL-1β levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment. - 予後改善を視野に入れた肝硬変のマネージメント 肝硬変症例における息切れ評価とmodified MRC Gradeを用いたPoPH拾い上げの試み
中井 正人; 荘 拓也; 坂本 直哉
肝臓, 63, Suppl.3, A666, A666, (一社)日本肝臓学会, Oct. 2022
Japanese - 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 免疫療法(単剤・複合療法)の効果は肝細胞癌のetiologyと関係するか
小川 浩司; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 坂本 直哉
肝胆膵, 85, 3, 393, 398, (株)アークメディア, Sep. 2022
Japanese - 切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療効果と肝予備能変化
荘 拓也; 出水 孝章; 目黒 高志; 中村 晃久; 上林 実; 高木 智史; 馬場 英; 古家 乾; 鈴木 和治; 山本 義也; 伊藤 淳; 山田 錬; 宮城島 拓人; 須田 剛生; 大原 正嗣; 中井 正人; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 39, 39, 日本消化器病学会-北海道支部, Sep. 2022
Japanese - 肝血管筋脂肪腫の1切除例
佐々木 貴志; 甲谷 理紗子; 細田 峻一; 吉田 苑永; 得地 祐匡; 久保 彰則; 大原 正嗣; 須田 剛生; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉; 相山 健; 武冨 紹信; 岡崎 ななせ; 松野 吉宏
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 40, 40, 日本消化器病学会-北海道支部, Sep. 2022
Japanese - 日本人肥満2型糖尿病における腹腔鏡下スリーブ状胃切除術が脂肪肝と膵β細胞機能に及ぼす効果 前向きコホート研究
大江 悠希; 中村 昭伸; 曹 圭龍; 高瀬 崇宏; 小川 浩司; 海老原 裕磨; 吉川 仁人; 西田 睦; 宮 愛香; 野本 博司; 亀田 啓; 荘 拓也; 須田 剛生; 倉島 庸; 阿保 大介; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
糖尿病合併症, 36, Suppl.1, 172, 172, (一社)日本糖尿病合併症学会, Sep. 2022
Japanese - 肝硬変体液貯留に対するトルバプタン投与症例における尿NGAL測定の有用性
中井 正人; 森川 賢一; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 大原 正嗣; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉
肝臓, 63, Suppl.2, A592, A592, (一社)日本肝臓学会, Sep. 2022
Japanese - Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
Cancers, 14, 16, 3938, 3938, MDPI AG, 15 Aug. 2022
Scientific journal, The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 ± 0.43 vs. −2.18 ± 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed. - VALIDATION OF THE EASY-TO-USE LENVATINIB PROGNOSTIC (LEP) INDEX TO PREDICT PROGNOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB.
Margherita Rimini; Wonseok Kang; Valentina Burgio; Mara Persano; Tamoko Aoki; Shigeo Shimose; Toshifumi Tada; Takashi Kumada; Takuya Sho; Eleonora Lai; Ciro Celsa; Claudia Campani; Matteo Tonnini; Emiliano Tamburini; Atsushi Hiraoka; Koichi Takaguchi; Naoshi Nishida; Hideki Iwamoto; Ei Itobayashi; Kunihiko Tsuji; Naoya Sakamoto; Toru Ishikawa; Hidenori Toyoda; Masatoshi Kudo; Takumi Kawaguchi; Takeshi Hatanaka; Kazugiro Nouso; Goki Suda; Giuseppe Cabibbo; Fabio Marra; Angelo Della Corte; Francesca Ratti; Federica Pedica; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Hepatology research : the official journal of the Japan Society of Hepatology, 12 Aug. 2022, [International Magazine]
English, Scientific journal, BACKGROUND: The identification of new prognostic factors able to stratify HCC patients candidate to first line therapy is an urgent. In the present work we validated the prognostic value of the LEP index. MATHERIALS AND METHODS: Data of Eastern and Western patients treated with lenvatinib as first-line for BCLC stage B or C HCC were recollected. LEP index was composed by three class of risk according with our previously study. The 'low risk'group includes patients with PNI >43.3 and with previous TACE. The 'medium risk' group includes patients with PNI >43.3 but without previous TACE and patients with PNI <43.3, ALBI grade 1 and BCLC-B. The 'high risk'group includes patients with PNI <43.3, ALBI grade 2 and patients with PNI <43.3, ALBI grade 1 and BCLC-C. RESULTS: 717 patients were included. Median OS was 20.7 months (95% CI 16.1-51.6) in patients with low risk (n = 223), 16.7 months (95% CI 13.3-47.0) in medium risk (n = 264) and 10.7 months (95% CI 9.3-12.2) in high risk (n = 230) [HR 1, 1.29 and 1.92 respectively; p < 0.0001]. Median PFS was 7.3 months (95% CI 6.3-46.5) in patients with low risk, 6.4 months (95% CI 5.3-8.0) in medium and 4.9 months (95% CI 4.3-5.5) in high risk [HR 1, 1.07, 1.47 respectively; p = 0.0009]. CONCLUSION: The LEP index confirms its prognostic value on an external cohort of HCC patients treated with Lenvatinib. This article is protected by copyright. All rights reserved. - Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma.
Masato Nakai; Kenichi Morikawa; Shunichi Hosoda; Sonoe Yoshida; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Masatsugu Ohara; Takuya Sho; Goki Suda; Koji Ogawa; Naoya Sakamoto
World journal of hepatology, 14, 7, 1480, 1494, 27 Jul. 2022, [International Magazine]
English, Scientific journal, BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC. - Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
Machiko Umemura; Koji Ogawa; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Tomoe Shimazaki; Megumi Kimura; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Kota Ono; Kazumoto Murata; Masaya Sugiyama; Masashi Mizokami; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 586, 596, Jul. 2022, [International Magazine]
English, Scientific journal, BACKGROUND & AIMS: Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects of NAs on HBsAg reduction and association with serum IFN-λ3 levels in chronic hepatitis B (CHB) patients. METHODS: A total of 91 patients [51 treated with nucleoside analog entecavir hydrate (ETV) and 40 treated with nucleotide analog adefovir dipivoxil (ADV) or tenofovir disoproxil fumarate (TDF)] with clinically evident CHB (chronic hepatitis, 57; liver cirrhosis, 34) were enrolled in this study. Serum IFN-λ3 levels among patients receiving ETV and ADV/TDF were measured before the initiation of therapy and 1, 3, and 5 years post-therapy. RESULTS: The change (mean ± standard deviation) in serum HBsAg levels from baseline to year five was -0.38 ± 0.46 and -0.84 ± 0.64 log10 IU/ml in ETV and ADV/TDF groups, respectively (p = 0.0004). Higher serum IFN-λ3 levels were observed in ADV/TDF group compared with ETV group during treatment (p < 0.001). Serum IFN-λ3 levels showed negative correlation with HBsAg reduction in ADV/TDF group (r = -0.386, p = 0.038) at week 48. Nucleotide analogs (ADV/TDF) treatment has associated factors with -0.3 log HBsAg decline at 1 year, -0.5 log HBsAg decline at 3 years, and -0.8 log HBsAg decline at 5 years after NAs treatment on multivariate analysis. CONCLUSIONS: Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction. - Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia
Michiko Takimoto-Sato; Toshinari Miyauchi; Masaru Suzuki; Hideyuki Ujiie; Toshifumi Nomura; Tomoo Ikari; Tomohiko Nakamura; Kei Takahashi; Machiko Matsumoto-Sasaki; Hirokazu Kimura; Hiroki Kimura; Yuichiro Matsui; Takashi Kitagataya; Ren Yamada; Kazuharu Suzuki; Akihisa Nakamura; Masato Nakai; Takuya Sho; Koji Ogawa; Naoya Sakamoto; Naoko Yamaguchi; Noriyuki Otsuka; Utano Tomaru; Satoshi Konno
Frontiers in Genetics, 13, Frontiers Media SA, 05 May 2022
Scientific journal, Background: Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP) is an extremely rare disease caused by mutations in FAM111B, and only approximately 30 cases have been reported worldwide. Some patients develop interstitial pneumonia, which may lead to progressive pulmonary fibrosis and poor prognosis. However, no effective treatment for interstitial pneumonia associated with POIKTMP has been reported. Here, we report an autopsy case of POIKTMP, wherein interstitial pneumonia was improved by corticosteroids.
Case Presentation: A 44-year-old Japanese man was referred to our hospital due to poikiloderma, hypotrichosis, and interstitial pneumonia. He developed progressive poikiloderma and muscle weakness since infancy. He also had tendon contractures, short stature, liver cirrhosis, and interstitial pneumonia. Mutation analysis of FAM111B revealed a novel and de novo heterozygous missense mutation, c.1886T > G (p(Phe629Cys)), through which we were able to diagnose the patient with POIKTMP. 3 years after the POIKTMP diagnosis, interstitial pneumonia had worsened. After 2 weeks of administrating 40 mg/day of prednisolone, his symptoms and lung shadows improved. However, he subsequently developed severe hepatic encephalopathy and eventually died of respiratory failure due to bacterial pneumonia and pulmonary edema. Autopsy revealed an unclassifiable pattern of interstitial pneumonia, as well as the presence of fibrosis and fatty degeneration in several organs, including the liver, kidney, skeletal muscle, heart, pancreas, and thyroid.
Conclusions: We report a case of POIKTMP in which interstitial pneumonia was improved by corticosteroids, suggesting that corticosteroids could be an option for the treatment of interstitial pneumonia associated with this disease. - 日本人肥満2型糖尿病における腹腔鏡下スリーブ状胃切除術が脂肪肝に及ぼす効果 前向きコホート研究
大江 悠希; 高瀬 崇宏; 曹 圭龍; 小川 浩司; 海老原 裕磨; 吉川 仁人; 西田 睦; 宮 愛香; 野本 博司; 亀田 啓; 荘 拓也; 須田 剛生; 中村 昭伸; 倉島 庸; 阿保 大介; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明
糖尿病, 65, Suppl.1, S, 139, (一社)日本糖尿病学会, Apr. 2022
Japanese - Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis.
Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Megumi Kimura; Zijian Yang; Osamu Maehara; Qingjie Fu; Shunichi Hosoda; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 7, 603, 613, 30 Mar. 2022, [International Magazine]
English, Scientific journal, AIM: A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact of overestimated renal function on prognosis in patients with LC. METHODS: An overestimated renal function was defined as a >20% increase in the creatinine-based estimated glomerular filtration rate (eGFR), compared with cystatin C-based eGFR. LC patients with conserved serum, who were evaluated for muscle atrophy and had proper clinical information were included, and their prognostic factors were analyzed. RESULTS: A total of 215 consecutive patients with LC were included. The prevalence of overestimated renal function was 29.8% (64/215). Kaplan-Meier survival analysis revealed that patients with overestimated renal function had a poorer prognosis than those without overestimated renal function (hazard ratio [HR]: 2.217 95% confidence interval [CI]: 1.290-3.810; P=0.001). Subgroup analysis showed that overestimated renal function was a significant prognostic factor, irrespective of sex and the presence of hepatocellular carcinoma (HCC). Multivariate Cox regression analyses revealed that overestimated renal function was a significant and independent factor predictive of poor prognosis in the entire cohort (HR: 2.050; 95% CI: 1.041-4.037; P=0.038) and in subgroups classified by Child-Pugh class A (HR: 2.131; 95% CI: 1.019-4.458; P=0.044), Model for End-Stage Liver Disease score <9 (HR: 2.303; 95% CI: 1.038-5.109; P=0.04), and presence of HCC (HR: 2.290; 95% CI: 1.128-4.651; P=0.022). CONCLUSION: Overestimated renal function is a significant and independent prognostic factor in patients with LC. This article is protected by copyright. All rights reserved. - 再活性化が疑われた急性E型肝炎の1例
久保 彰則; 小川 浩司; 吉田 苑永; 細田 峻一; 得地 祐匡; 山田 錬; 北潟谷 隆; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 石田 勢津子; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 55, 55, 日本消化器病学会-北海道支部, Mar. 2022
Japanese - 若年女性に見られた肝細胞腺腫症の1例
北潟谷 隆; 吉田 苑永; 細田 俊一; 久保 彰則; 得地 祐匡; 山田 錬; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 高桑 恵美; 中島 収
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 56, 56, 日本消化器病学会-北海道支部, Mar. 2022
Japanese - 肝癌に対する新世代マイクロ波凝固療法の治療成績
中井 正人; 吉田 苑永; 細田 峻一; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 70, 70, 日本消化器病学会-北海道支部, Mar. 2022
Japanese - The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Akihisa Nakamura; Koji Yamamoto; Rei Takeda; Ren Yamada; Akinori Kubo; Kenichi Morikawa; Sayaka Ando; Tomoe Shimazaki; Takaaki Izumi; Machiko Umemura; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Megumi Kimura; Masato Nakai; Takuya Sho; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Toshiro Sugiyama; Hiroshi Takeda; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 52, 6, 508, 521, 07 Feb. 2022, [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: Although various noninvasive markers and prediction formulas for nonalcoholic steatohepatitis (NASH) have been reported, they are of value only in the diagnosis of the advanced fibrosis stage of NASH. In this study, we evaluated soluble CD14 (sCD14) as a diagnostic marker for discriminating NASH from nonalcoholic fatty liver disease (NAFLD) using an animal model and clinical specimens. METHODS: Serum sCD14 levels were measured in samples derived from mice with diet-induced NASH and patients using an enzyme-linked immunosorbent assay. Our cohort enrolled 126 patients with liver needle biopsy-proven NAFLD. RESULTS: The intestinal defense mechanism in NASH model mice was altered as a consequence of the unique gut environment. Elevated serum levels of sCD14 were observed in mice with diet-induced NASH, and the condition of the liver was exacerbated as a result of exposure to gut-derived endotoxin. We confirmed that the serum sCD14 levels in NAFL patients significantly differed from those in NASH patients. The area under the curve for distinguishing between NAFL and NASH was 0.891. Moreover, we found that serum sCD14 levels were weakly correlated with the inflammation grade based on the NAFLD activity score (NAS), the grade of fibrosis according to the Brunt fibrosis classification, and a positive correlation with the grade of ballooning based on NAS in patients with NAFLD. CONCLUSION: sCD14 could be a useful pathophysiological marker and diagnostic adjunct distinguishing NASH from NAFLD. The use of sCD14 may allow the screening and identification of high-risk groups for NASH development and support early therapeutic interventions. - Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Masato Nakai; Yoshiya Yamamoto; Masaru Baba; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Ken Furuya; Naoya Sakamoto
Scientific reports, 12, 1, 1449, 1449, 27 Jan. 2022, [International Magazine]
English, Scientific journal, Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age ≥ 71 years (hazard ratio [HR]: 3.402) and LSM ≥ 9.2 kPa (HR: 6.328); SVR24 factors were age ≥ 71 years (HR: 2.689) and LSM ≥ 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (≥ 9.2 kPa) and SVR24 LSM (≥ 8.4 kPa) and age (≥ 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up. - Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang; Goki Suda; Osamu Maehara; Masatsugu Ohara; Sonoe Yoshida; Shunichi Hosoda; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 14, 1, 04 Jan. 2022, [International Magazine]
English, Scientific journal, Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS. - Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Satoshi Abiko; Kenji Kinoshita; Shuichi Miyamoto; Ryo Sugiura; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
PloS one, 17, 1, e0261760, 2022, [International Magazine]
English, Scientific journal, For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6-12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population. - Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
Masato Nakai; Goki Suda; Koji Ogawa; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Masatsugu Ohara; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
PloS one, 17, 7, e0270786, 2022, [International Magazine]
English, Scientific journal, Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin against CHE is not thoroughly investigated in Japanese patients. We aimed to investigate the efficacy of rifaximin against hyperammonemia and CHE in Japan. We observed 102 patients with HE showing hyperammonemia secondary to LC and examined various biochemical and behavioral parameters following rifaximin treatment. CHE was diagnosed when the patients exhibited two or more abnormal neuropsychological test (NPT) scores but did not indicate OHE symptoms. In the 102 cases, a significant therapeutic effect of rifaximin on hyperammonemia was observed from 2 to 48 weeks after starting treatment. Excluding 10 patients diagnosed with OHE upon starting rifaximin treatment, 12 of the 92 remaining patients (11.8%) transitioned to OHE within 1 year. The 1 year cumulative OHE transition rate was 14.5%. Among the 24 patients with CHE diagnosed by the NPT for whom NPT results could be evaluated at 4 and 12 weeks after starting treatment, 10 (41.6%) had recovered from CHE at 12 weeks. When the factors contributing to recovery from CHE were examined by multivariate analysis, an ammonia level <129 μg/dL was a significant factor. Rifaximin was thus significantly effective against both hyperammonemia and CHE in Japanese patients. - Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
Takuya Sho; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Mugumi Kimura; Masato Nakai; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
World journal of gastrointestinal oncology, 13, 12, 2076, 2087, 15 Dec. 2021, [International Magazine]
English, Scientific journal, The phase III clinical trial of the novel molecular targeted agent (MTA) lenvatinib for patients with advanced hepatocellular carcinoma (HCC) (REFLECT trial) found that lenvatinib was non-inferior to sorafenib in overall survival. Recently, the efficacy of multiple MTAs, including lenvatinib, in practice has been reported, and therapeutic strategies for Barcelona Clinic Liver Cancer (BCLC) intermediate stage HCC are undergoing major changes. Based on these results, lenvatinib could be recommended for patients with transcatheter arterial chemoembolization (TACE)-refractory, ALBI grade 1, within the up-to-seven criteria in the BCLC intermediate stage. Lenvatinib provides a more favorable outcome than TACE, even in cases with large or multinodular HCC beyond the up-to-seven criteria with Child-Pugh grade A. When patients meet the definitions of TACE-refractory or TACE-unsuitable, switching to systemic chemotherapy, including lenvatinib, is for favorable for preserving liver function. If initial treatment, including MTA, has a significant therapeutic effect and downstaging of HCC is obtained, additional TACE or surgical resection should be considered. Lenvatinib also has a therapeutic effect for poorly differentiated type and non-simple nodular type HCC thanks to the survival-prolonging effect of this drug. Furthermore, a significant therapeutic effect is expected in tumors with more than 50% liver involvement or main portal vein invasion, which have traditionally been considered to have a poor prognosis in patients. This suggests that at the start of lenvatinib treatment, HCC patients with ALBI grade 1 may be able to maintain liver functional reserve. - Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Akinori Kubo; Sonoe Yoshida; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Masatsugu Ohara; Ren Yamada; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Scientific Reports, 11, 1, Springer Science and Business Media LLC, Dec. 2021
Scientific journal,Abstract We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305,P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels.l -carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA. - 特集 肝不全・肝硬変に対する再生療法-最先端の今 4.開発中の肝再生医療(7)肝星細胞に対するビタミンAを介した肝線維化改善療法の開発
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
臨床消化器内科, 36, 13, 1690, 1694, 日本メディカルセンター, 20 Nov. 2021 - 【肝胆膵疾患におけるバイオマーカーの意義を探る】肝疾患のバイオマーカー NASHにおける新規糖鎖バイオマーカー(AAT-A3F)
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 83, 4, 527, 533, (株)アークメディア, Oct. 2021
Japanese - 当院における切除不能肝細胞癌に対するAtezolizumab+Bevacizumab併用療法の使用経験
吉田 苑永; 荘 拓也; 久保 彰則; 得地 祐匡; 細田 峻一; 北潟谷 隆; 山田 錬; 中井 正人; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 40, 40, 日本消化器病学会-北海道支部, Sep. 2021
Japanese - Lenvatinib加療後にCRに至りconversion surgeryを施行した肝内多発転移を伴う肝細胞癌の1例
細田 峻一; 中井 正人; 吉田 苑永; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 岡崎 ななせ; 大塚 拓也; 三橋 智子
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 129回・123回, 42, 42, 日本消化器病学会-北海道支部, Sep. 2021
Japanese - Transient elastographyによるLSMと年齢を用いたSVR後肝発癌低リスク群の囲い込み
中井 正人; 山本 義也; 馬場 英; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 古家 乾; 坂本 直哉
肝臓, 62, Suppl.2, A543, A543, (一社)日本肝臓学会, Sep. 2021
Japanese - 除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療経験:多施設共同研究
荘 拓也; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 62, Suppl.2, A550, A550, (一社)日本肝臓学会, Sep. 2021
Japanese - Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Taku Shigesawa; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Jun Ito; Takuto Miyagishima; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 9, 979, 989, Sep. 2021, [International Magazine]
English, Scientific journal, AIM: A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real-world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria. METHODS: In this multicenter study, patients with unresectable HCC treated with atezolizumab plus bevacizumab between October 2020 and May 2021 were screened. In patients who did not meet IMbrave150 eligibility criteria, treatment responses and safety at 6 and 12 weeks were evaluated. RESULTS: Atezolizumab plus bevacizumab was initiated in 64 patients, including 46 patients (71.9%) who did not meet IMbrave150 eligibility criteria. Most of these patients had a history of systemic therapy (44/46). The objective response rate and disease control rate observed using Response Evaluation Criteria in Solid Tumors 1.1 were 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively; these rates were similar between patients who met and did not meet the IMbrave150 criteria. Ten patients experienced progressive disease (PD) at 6 weeks. Portal vein tumor thrombosis was significantly associated with PD (p = 0.039); none of the 15 patients with hepatitis B virus-related HCC experienced PD (p = 0.050). The most common adverse events of grade 3 or higher were aspartate aminotransferase elevation (n = 8, 13.8%) and the safety profile was similar between patients who met and did not meet the IMbrave150 criteria. CONCLUSION: Most patients treated with atezolizumab plus bevacizumab did not meet the IMbrave150 criteria; however, the combination therapy showed good safety and efficacy at the early treatment phase. - 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 アテゾリズマブ+ベバシズマブによるCR例の特徴
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 83, 2, 259, 263, (株)アークメディア, Aug. 2021
Japanese - 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 アテゾリズマブ+ベバシズマブによるCR例の特徴
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 83, 2, 259, 263, (株)アークメディア, Aug. 2021
Japanese - Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.
Yusuke Uchinami; Norio Katoh; Daisuke Abo; Hiroshi Taguchi; Koichi Yasuda; Kentaro Nishioka; Takeshi Soyama; Ryo Morita; Naoki Miyamoto; Ryusuke Suzuki; Takuya Sho; Masato Nakai; Koji Ogawa; Tatsuhiko Kakisaka; Tatsuya Orimo; Toshiya Kamiyama; Shinichi Shimizu; Hidefumi Aoyama
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 870, 879, Aug. 2021, [International Magazine]
English, Scientific journal, AIM: To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. METHODS: From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score ≥9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. RESULTS: With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs. ≥2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 ≥100 Gy group than in the BED10 <100 Gy group (2-year 100% vs. 86.5%, p = 0.049) at the reference point. CONCLUSION: This retrospective study of stereotactic body radiotherapy using real-time tumor-tracking radiotherapy for hepatocellular carcinoma showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 ≥100 Gy to the reference point. - Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Akinori Kubo; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Cancers, 13, 14, 20 Jul. 2021, [International Magazine]
English, Scientific journal, In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOB-MRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. - Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.
Sonoe Yoshida; Goki Suda; Masatsugu Ohara; Qingjie Fu; Zijian Yang; Shunichi Hosoda; Megumi Kimura; Kubo Akinori; Yoshimasa Tokuchi; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Osamu Maehara; Shunsuke Ohnishi; Naoya Sakamoto
Nutrients, 13, 7, 14 Jul. 2021, [International Magazine]
English, Scientific journal, Renal dysfunction and sarcopenia are important prognostic factors in patients with chronic liver disease (CLD). Muscle atrophy can cause the overestimation of renal function based on serum creatinine. However, the frequency of overestimated renal function in Japanese patients with CLD and its relationship with sarcopenia are unclear. In present study, we evaluated the frequency of overestimated renal function, defined as a >20% higher eGFR using creatinine than using cystatin C, in 307 patients with CLD as well as its relationship with indicators of sarcopenia. In total, 24.8% of patients had overestimated renal function. In a multivariate regression analysis, liver cirrhosis (p = 0.004) and psoas muscle mass index (p = 0.049) were significantly associated with overestimated renal function. Loss of skeletal muscle mass was significantly more frequent in both male and female patients with overestimated renal function than without. In males, the loss of muscle strength and rate of sarcopenia, defined as loss of muscle mass and strength, were significantly higher in patients with than without overestimated renal function. The high frequency of overestimated renal function in Japanese patients suggests that indicators of renal function should be carefully considered; furthermore, monitoring and interventions for both renal function and sarcopenia are needed in patients with CLD. - 【ガイドライン2020から読み解くNAFLD/NASH】診断 NAFLD/NASHの超音波診断
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 83, 1, 67, 73, (株)アークメディア, Jul. 2021
Japanese - 【ガイドライン2020から読み解くNAFLD/NASH】診断 NAFLD/NASHの超音波診断
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 83, 1, 67, 73, (株)アークメディア, Jul. 2021
Japanese - FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Taku Shigesawa; Gouki Kanbe; Megumi Kimura; Masaya Sugiyama; Masashi Mizokami; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Naoto Okubo; Shunsuke Ohnishi; Hiroshi Takeda; Naoya Sakamoto
Cancer biology & therapy, 22, 5-6, 372, 380, 03 Jun. 2021, [International Magazine]
English, Scientific journal, Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for signaling to maintain cancer stem-like cells (CSCs) in esophageal squamous cell carcinoma (ESCC). However, which FGF receptor, 1, 2, 3, 4, and L1, is essential or whether FGFRs have distinct different roles in ESCC-CSCs is still in question. This study shows that FGFR2, particularly the IIIb isoform, is highly expressed in non-CSCs. Non-CSCs have an epithelial phenotype, and such cells are more differentiated in ESCC. Further, FGFR2 induces keratinocyte differentiation through AKT but not MAPK signaling and diminishes CSC populations. Conversely, knockdown of FGFR2 induces epithelial-mesenchymal transition (EMT) and enriches CSC populations in ESCC. Finally, data analysis using The Cancer Genome Atlas (TCGA) dataset shows that expression of FGFR2 significantly correlated with cancer cell differentiation in clinical ESCC samples. The present study shows that each FGFR has a distinct role and FGFR2-AKT signaling is a key driver of keratinocyte differentiation in ESCC. Activation of FGFR2-AKT signaling could be a future therapeutic option targeting CSC in ESCC. - Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
Yoshimasa Tokuchi; Goki Suda; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal of viral hepatitis, 28, 5, 755, 763, May 2021, [International Magazine]
English, Scientific journal, Hepatitis C virus (HCV) infection can cause renal dysfunction, expected to improve upon HCV eradication. However, adverse effects of HCV eradication using direct-acting antiviral agents (DAAs) on renal function have been recently reported. This retrospective study aimed to evaluate renal function with glomerular filtration rate (eGFR) estimated using creatinine (eGFRcre) and cystatin C (eGFRcys). Complete clinical information and preserved serum samples were collected from 207 patients with HCV infection treated with interferon-free DAA at baseline and SVR48 (SVR48). Patients who underwent paired computed tomography (CT) at baseline and ≥12 months after DAA were evaluated for changes in skeletal muscle mass using the psoas muscle mass index (PMI). eGFRcre significantly worsened at SVR48, while eGFRcys was similar at baseline and SVR48. At baseline, eGFRcre was significantly higher than eGFRcys; eGFRcre and eGFRcys were similar at SVR48. Multivariate analysis revealed that the presence of liver cirrhosis and low-albumin level, as well as cirrhosis and age, was significantly associated with the overestimation of renal function by eGFRcre at baseline and SVR48, respectively. In the 57 patients who underwent paired CT at baseline and ≥12 months after DAA, relative values of PMI significantly increased after DAA. After DAA, in patients with increased PMI (65% 37/57), eGFRcre significantly worsened but did not change in patients without increased PMI. eGFRcre significantly worsened after DAAs; however, this might not reflect accurate changes in renal function, partially because of changes in skeletal muscle mass. eGFRcys did not change after DAAs, and it is a potential alternative to eGFRcre. - Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Ren Yamada; Yoshimasa Tokuchi; Akinori Kubo; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Masatsugu Ohara; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
Scientific reports, 11, 1, 9207, 9207, 28 Apr. 2021, [International Magazine]
English, Scientific journal, We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy. - 肝疾患移行期医療の現状と問題点 フォンタン術後肝合併症の現状と5年経過からみえてくること
荘 拓也; 森川 賢一; 坂本 直哉
肝臓, 62, Suppl.1, A167, A167, (一社)日本肝臓学会, Apr. 2021
Japanese - 部分的脾動脈塞栓術(PSE)、バルーン閉塞下逆行性経静脈的塞栓術(B-RTO)の肝予備能、線維化マーカー、予後への影響
中井 正人; 小川 浩司; 坂本 直哉; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一
肝臓, 62, Suppl.1, A332, A332, (一社)日本肝臓学会, Apr. 2021
Japanese - 胆嚢転移を来した原発性肝細胞癌再発の1例
得地 祐匡; 須田 剛生; 久保 彰則; 北潟谷 隆; 山田 錬; 重沢 拓; 中井 正人; 荘 拓也; 小川 浩司; 森川 賢一; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 57, 57, 日本消化器病学会-北海道支部, Mar. 2021
Japanese - 経過観察中に増大傾向がみられ、肝切除術に至った肝原発神経内分泌腫瘍の1例
久保 彰則; 小川 浩司; 得地 祐匡; 山田 錬; 北潟谷 隆; 重沢 拓; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 58, 58, 日本消化器病学会-北海道支部, Mar. 2021
Japanese - 肝機能障害を契機に診断された肝ヘモクロマトーシスの一例
吉田 苑永; 中井 正人; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 128回・122回, 67, 67, 日本消化器病学会-北海道支部, Mar. 2021
Japanese - Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal of gastroenterology, 56, 2, 168, 180, Feb. 2021, [Domestic magazines]
English, Scientific journal, BACKGROUND: Entecavir and tenofovir-disoproxil-fumarate are first-line nucleos(t)ide analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term administration can impact extrahepatic organs. Herein, we sought to examine the effect of NA on lipid metabolism while also characterizing the associated mechanism. METHODS: A retrospective study was performed on HBV patients administered entecavir or tenofovir-disoproxil-fumarate. Patient clinical information, as well as their preserved serum samples obtained at baseline and 6-12 months after treatment initiation, were analyzed. A 1:1 propensity score matching was applied to the assignment of tenofovir-disoproxil-fumarate or entecavir treatment. Changes in serum cholesterol, including oxidized-LDL, were analyzed. Subsequently, in vitro analysis elucidated the mechanism associated with the effect of NAs on lipid metabolism. RESULTS: Administration of tenofovir-disoproxil-fumarate, not entecavir, to chronic HBV patients, decreased serum cholesterol levels, including non-HDL and oxidized-LDL, which are strongly associated with arteriosclerosis. In vitro analysis revealed that tenofovir-disoproxil-fumarate reduced supernatant cholesterol, and upregulated the scavenger receptor, CD36, in hepatocytes. Meanwhile, silencing of hepatic CD36 increased supernatant cholesterol and negated the cholesterol-reducing effect of tenofovir-disoproxil-fumarate in HepG2-cells. Reporter, microarray, and RT-PCR analyses further revealed that tenofovir-disoproxil-fumarate treatment activates PPAR-α-mediated signaling, and upregulates PPAR-α target genes, including CPT1 and CD36. Alternatively, silencing of PPAR-α reversed the effects of tenofovir-disoproxil-fumarate on CD36. CONCLUSIONS: Tenofovir-disoproxil-fumarate modulates lipid metabolism by upregulating hepatic CD36 via PPAR-α activation. Since dyslipidemia could be associated with arteriosclerosis and hepatocarcinogenesis, these discoveries provide novel insights into anti-HBV therapies, as well as the associated extrahepatic effects of NA. - 【肝・胆道系症候群(第3版)-その他の肝・胆道系疾患を含めて-肝臓編(上)】血行異常 肝内動静脈短絡(A-V shunt)
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本臨床, 別冊, 肝・胆道系症候群I, 303, 306, (株)日本臨床社, Jan. 2021
Japanese - Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Taku Shigesawa; Goki Suda; Megumi Kimura; Osamu Maehara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Ken Furuya; Masaru Baba; Takashi Kitagataya; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
PloS one, 16, 3, e0247728, 2021, [International Magazine]
English, Scientific journal, A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks after lenvatinib initiation. Patients with adequate clinical data and baseline preserved serum samples available were included. Baseline fibroblast growth factor (FGF)19 and 21, angiopoietin (ANG)2, and vascular endothelial growth factor (VEGF) levels were evaluated. Thirty-seven patients were included, and 6, 15, 14, and 2 experienced complete response, partial response, stable disease, and progressive disease, respectively. Twenty-four (65%) and 13 (35%) patients showed a maintained/improved and deteriorated Child-Pugh-score, respectively. While baseline clinical data, treatment response, and laboratory data were similar between these two patient groups, baseline ANG2 and VEGF levels were significantly higher (P = 0.0017) and lower (P = 0.0231), respectively, in patients with deteriorated Child-Pugh score than in those without. Based on receiver operating characteristic curve analysis, cut-off values for ANG2 and VEGF were found to be 3,108 pg/mL and 514.9 pg/mL, respectively. Among patients with low VEGF and high ANG2, 89% (8/9) exhibited a deteriorated Child-Pugh score, whereas none of the patients (0/9) with high VEGF and low ANG2 did. The deterioration of the Child-Pugh score in patients with unresectable HCC who are treated with lenvatinib may be predictable based on combined baseline serum ANG2 and VEGF levels. - Durable response without recurrence to Tolvaptan improves long-term survival.
Masato Nakai; Goki Suda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal of gastroenterology, 55, 12, 1150, 1161, Dec. 2020, [Domestic magazines]
English, Scientific journal, BACKGROUND: Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water retention associated with cirrhosis. However, despite the short-term response, water retention recurrence is still observed in some cases. This study aimed to clarify the water retention recurrence rate and the relationship between long-term response without recurrence and prognosis. METHODS: Altogether, 100 patients with decompensated cirrhosis treated with tolvaptan were retrospectively analyzed. Recurrence was evaluated according to the criteria of the EASL clinical practice guideline. The recurrence rate and prognosis of non-responders, patients with recurrence, and long-term responders were analyzed. The baseline factors related to short-term response, recurrence, and long-term response were also evaluated. RESULTS: Approximately 31.0% of the short-term responders had recurrence. Although there was no significant difference in the prognosis by short-term response (p = 0.07), the long-term responders had a significantly better prognosis than those with recurrence and non-responders (p < 0.01). Low CRP levels and high urinary Na/K ratios were significant factors related to short-term response, and the presence of acute kidney injury was also a factor related to non-response. The low CRP level (relapse: < 1.10 mg/dl, long-term response: < 0.94 mg/dl) was identified as a factor related to recurrence and long-term response. CONCLUSION: The long-term responders without recurrence had a significantly better prognosis. CRP was a useful predictor for long-term response, whereas renal function parameters were useful predictors for short-term response. Inflammation control may be important for long-term response and prognosis in cirrhosis patients with water retention. - 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】カボザンチニブ CELESTIAL試験の総括とサブ解析
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 81, 5, 986, 992, (株)アークメディア, Nov. 2020
Japanese - 当院における門脈血栓症に対するアンチトロンビンIII製剤の使用成績
北潟谷 隆; 小川 浩司; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 44, 44, 日本消化器病学会-北海道支部, Oct. 2020
Japanese - ソホスブビル/ベルパタスビル投与によりSVR12が得られたC型非代償性肝硬変の1例
山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 127回・121回, 45, 45, 日本消化器病学会-北海道支部, Oct. 2020
Japanese - 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part I-(免疫療法)】免疫チェックポイント阻害剤による単剤治療 進行肝細胞癌に対するニボルマブ第III相試験(CheckMate 459試験)のUpdate results
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝胆膵, 81, 4, 651, 657, (株)アークメディア, Oct. 2020
Japanese - 肝性脳症〜わが国における現状と課題〜 肝性脳症の疫学
中井 正人; 小川 浩司; 久保 彰則; 得地 祐匡; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本門脈圧亢進症学会雑誌, 26, 3, 75, 75, (一社)日本門脈圧亢進症学会, Oct. 2020
Japanese - Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
Goki Suda; Koji Ogawa; Megumi Kimura; Osamu Maehara; Takashi Kitagataya; Masatsugu Ohara; Yoshimasa Tokuchi; Akinori Kubo; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 50, 10, 1196, 1200, Oct. 2020, [International Magazine]
English, Scientific journal, AIM: Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19. METHODS: We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys Anti-SARS-CoV-2-assay (Roche Diagnostics). RESULTS: Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys were 98% (95% confidence interval [CI], 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys Anti-SARS-CoV-2 assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%). CONCLUSIONS: The Elecsys Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by the Elecsys Anti-SARS-CoV-2 assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020. - HCC既往の無いC型肝炎SVR後の初発肝発癌の囲い込み因子としての肝弾性度の有用性
中井 正人; 山本 義也; 馬場 英; 古家 乾; 北潟谷 隆; 山田 錬; 重沢 拓; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 61, Suppl.2, A682, A682, (一社)日本肝臓学会, Sep. 2020
Japanese - 免疫チェックポイント阻害剤関連肝炎の頻度、予測因子、臨床経過の検討
北潟谷 隆; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 61, Suppl.2, A705, A705, (一社)日本肝臓学会, Sep. 2020
Japanese - Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease
Masatsugu Ohara; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
JCSM Rapid Communications, 3, 2, 103, 114, Wiley, Jul. 2020
Scientific journal - 進行肝細胞癌に対するREFLECT内/外におけるレンバチニブの治療効果と安全性の検討
荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉
日本消化器病学会雑誌, 117, 臨増総会, A253, A253, (一財)日本消化器病学会, Jul. 2020
Japanese - 部分的脾動脈塞栓術(PSE)により肝予備能は改善するか
中井 正人; 小川 浩司; 北潟谷 隆; 山田 錬; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
日本消化器病学会雑誌, 117, 臨増総会, A367, A367, (一財)日本消化器病学会, Jul. 2020
Japanese - Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Takuya Sho; Goki Suda; Koji Ogawa; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Jun Ito; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Katsumi Terasita; Tomofumi Takagi; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 20 Jun. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, AIM: This study aimed to determine the efficacy and safety of lenvatinib for patients with unresectable hepatocellular carcinoma (HCC) who did not meet REFLECT eligibility criteria (phase 3 clinical trial). METHODS: In this multicenter retrospective study, patients with unresectable HCC treated with lenvatinib between 2018 and 2019 and had adequate clinical data were included. Objective-response-rate (ORR), progression-free-survival (PFS), and safety were evaluated according to meeting or not meeting the REFLECT eligibility criteria and according to the criteria of the REFLECT trial. RESULTS: Of the 105 patients included, 61% (64/105) did not meet the REFLECT eligibility criteria. Safety and median PFS of lenvatinib were similar between the patients who did and those who did not meet the criteria. Among the patients who did not meet the criteria, 28, 27, 14, 6, 7, and 5 had a history of tyrosine kinase inhibitor (TKI) treatment, Child-Pugh score B, HCC in ≥50% of the liver, reduced platelet count, bile duct invasion, and main portal vein invasion. The efficacy and safety of lenvatinib for patients with or without Child-Pugh-score B or HCC in ≥50% of the liver were similar. Although treatment outcome was not significantly different, patients with TKI treatment history tended to have longer median PFS, whereas those with main portal vein invasion tended to have shorter median PFS. CONCLUSION: Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria. However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion. - Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR 1-3 signaling, but not FGFR4 signaling.
Taku Shigesawa; Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Megumi Kimura; Tomoe Shimazaki; Koji Yamamoto; Ren Yamada; Takashi Kitagataya; Akihisa Nakamura; Kazuharu Suzuki; Masatsugu Ohara; Naoki Kawagishi; Machiko Umemura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Masaya Sugiyama; Masashi Mizokami; Hiroshi Takeda; Naoya Sakamoto
Carcinogenesis, 42, 1, 58, 69, 25 May 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, In hepatocellular carcinoma (HCC), a subset of cells defined by high CD44 and CD133 expression has been reported to possess cancer stem-like cell (CSC) characteristics and to be associated with a poor prognosis. Since the approval of the multi-kinase inhibitor, lenvatinib, for patients with unresectable HCC, two such inhibitors (sorafenib and lenvatinib) have been employed as first-line systemic chemotherapeutics for these patients. Based on differences in the kinase-affinity profiles between these two drugs, evidence has suggested that both exert different effects on HCC, although these differences are not fully characterized. In this study, using in vitro and a preclinical in vivo xenograft mouse model, we showed that lenvatinib alone (not sorafenib or the cytotoxic agent, 5-fluorouracil) diminished CD44High/CD133High CSCs in HCC. Furthermore, western blotting and RT-PCR analysis revealed that the expression of fibroblast growth factor receptor (FGFR)-1 to 4 differed between CD44High/CD133High CSCs and control cells. Analysis of the effects of selective FGFR inhibitors and FGFR small interfering RNAs on CSCs in HCC revealed that lenvatinib diminished CSCs in HCC by inhibiting FGFR1-3 signaling, however, FGFR4 signaling was not impacted. Finally, we showed that FGF2 and FGF19 were involved in maintaining CD44High/CD133High CSCs in HCC, potentially, via FGFR1-3. The findings provide novel mechanistic insights into the effects of lenvatinib on CSCs in HCC and provide clues for developing effective targeted therapies against CSCs in HCC. - トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連
中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 61, Suppl.1, A347, A347, (一社)日本肝臓学会, Apr. 2020
Japanese - 大規模健常人データ(肝移植ドナー・検診受験者)を用いた低骨格筋量に対する最適psoas muscle mass index cut-off値検討と肝疾患患者における評価
須田 剛生; 大原 正嗣; 小川 浩司; 荘 拓也; 中井 正人; 森川 賢一; 坂本 直哉
肝臓, 61, Suppl.1, A474, A474, (一社)日本肝臓学会, Apr. 2020
Japanese - NAFLD患者におけるMRエラストグラフィ診断能の検討
山田 錬; 小川 浩司; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉
肝臓, 61, Suppl.1, A495, A495, (一社)日本肝臓学会, Apr. 2020
Japanese - 進行肝細胞癌に対するレンバチニブ治療成績からみた適格使用時期の検討 多施設共同研究
荘 拓也; 須田 剛生; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 川岸 直樹; 宮城島 拓人; 馬場 英; 古家 乾; 山本 義也; 小林 智絵; 目黒 高志; 高木 智史; 神山 俊哉; 武冨 紹信; 坂本 直哉
肝臓, 61, Suppl.1, A334, A334, (一社)日本肝臓学会, Apr. 2020
Japanese - Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
Taku Shigesawa; Goki Suda; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
JGH OPEN, Apr. 2020, [Peer-reviewed]
English, Scientific journal - Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
Masatsugu Ohara; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Tomoe Kobayashi; Minoru Uebayashi; Ryo Takagi; Isao Yokota; Tsuyoshi Shimamura; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 23 Mar. 2020, [Peer-reviewed], [International Magazine]
English, This study aimed to determine the optimal psoas muscle mass index (PMI) cut-off values for diagnosis of skeletal muscle mass loss. METHODS: We evaluated PMI in two groups of normal controls: a medical check-up group and a liver donation candidate group. We analyzed two novel PMI cut-off values, one based on the mean - two standard deviations (2SD) and one based on the lower 5%. Skeletal muscle mass index (SMI) evaluations using computed tomography (sliceOmatic; TomoVision) and bioelectrical impedance analysis and PMI evaluation were undertaken simultaneously. We analyzed the correlation between our PMI cut-off values and the Japan Society of Hepatology-defined SMI cut-off values. The prevalence of skeletal muscle mass loss in patients with liver disease was assessed using the novel PMI cut-off values. RESULTS: In 504 normal controls aged ≤50 years, the PMI cut-off values based on mean -2SD and the lower 5% were set at 3.30 cm2 /m2 for men and 1.69 cm2 /m2 for women and 3.74 cm2 /m2 for men and 2.29 cm2 /m2 for women, respectively. The PMI cut-off values based on the lower 5% alone showed that skeletal muscle mass loss increased with age. Furthermore, they correlated well with Japan Society of Hepatology-defined SMI (sliceOmatic) cut-off values and showed a significantly higher prevalence of skeletal muscle mass loss in patients with liver cirrhosis than those without liver cirrhosis. CONCLUSIONS: We propose the following PMI cut-off values: 3.74 cm2 /m2 for male individuals and 2.29 cm2 /m2 for female individuals. These cut-off values can facilitate accurate diagnosis and management of sarcopenia in patients with chronic liver disease. - Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara-Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, 18 Mar. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. - High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Naoki Kawagishi; Goki Suda; Megumi Kimura; Osamu Maehara; Tomoe Shimazaki; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Yusuke Kudo; Mutsumi Nishida; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 05 Feb. 2020, [Peer-reviewed], [International Magazine]
English, AIM: Factors associated with improvement of liver fibrosis after successful hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting antiviral agents (DAAs) have been not clarified well. Angiopoietin-2 (Ang2) is reported to be associated with vascular leak and inflammation observed in patients with advanced liver fibrosis. METHODS: In this retrospective study, patients treated with IFN-free DAAs who underwent transient elastography before and at 24-weeks post-treatment and achieved sustained viral response were enrolled. Baseline serum Ang2 was measured, and its relationship with other clinical factors was analyzed. Liver fibrosis stage was defined based on liver stiffness according to a previous report. Predictive factors for regression of liver fibrosis stage after DAA therapy were evaluated. RESULTS: Overall, 116 patients were analyzed. Baseline serum Ang2 levels were significantly associated with liver stiffness, spleen index, and liver stiffness-based liver fibrosis stage. Moreover, 75% of patients experienced regression of liver fibrosis stage after DAA therapy. Multivariate analysis revealed that advanced liver fibrosis stage and Ang2 levels were significantly associated with regression of liver fibrosis stage after DAA therapy. In patients with advanced liver fibrosis (F3/4), baseline Ang2 level alone could predict regression of liver fibrosis stage. A baseline Ang2 cut-off value (354 pg/ML) could predict regression of liver fibrosis stage after DAA therapy with high accuracy (sensitivity 0.882, specificity 0.733). CONCLUSIONS: Evaluation of serum Ang2 levels before DAA therapy is important. Our results provide a novel mechanistic insight into non-regression of liver stiffness after DAA therapy. Long-term and larger studies are required. - Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Hideki Yokoo; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
JGH OPEN, 4, 1, 54, 60, Feb. 2020, [Peer-reviewed]
English, Scientific journal - Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Takuya Sho; Goki Suda; Koji Ogawa; Megumi Kimura; Tomoe Shimazaki; Osamu Maehara; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kenichi Morikawa; Ken Furuya; Masaru Baba; Yoshiya Yamamoto; Tomoe Kobayashi; Takashi Meguro; Akiyoshi Saga; Takuto Miyagishima; Hideki Yokoo; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
JGH open : an open access journal of gastroenterology and hepatology, 4, 1, 54, 60, Feb. 2020, [Peer-reviewed], [International Magazine]
English - Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
Koji Ogawa; Takashi Kobayashi; Jun-Ichi Furukawa; Hisatoshi Hanamatsu; Akihisa Nakamura; Kazuharu Suzuki; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Masaru Baba; Ken Furuya; Katsumi Terashita; Tomoe Kobayashi; Manabu Onodera; Takahiro Horimoto; Keisuke Shinada; Seiji Tsunematsu; Izumi Tsunematsu; Takashi Meguro; Tomoko Mitsuhashi; Megumi Hato; Kenichi Higashino; Yasuro Shinohara; Naoya Sakamoto
Scientific reports, 10, 1, 321, 321, 15 Jan. 2020, [Peer-reviewed], [International Magazine]
English, Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that may lead to liver cirrhosis or hepatocellular carcinoma. Here, we examined the diagnostic utility of tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin (AAT-A3F), a non-invasive glycobiomarker identified in a previous study of NASH diagnosis. This study included 131 biopsy-proven Japanese patients with NAFLD. We evaluated the utility of AAT-A3F in NASH diagnosis, and conducted genetic analysis to analyse the mechanism of AAT-A3F elevation in NASH. Serum AAT-A3F concentrations were significantly higher in NASH patients than in NAFL patients, and in patients with fibrosis, lobular inflammation, and ballooning. Hepatic FUT6 gene expression was significantly higher in NASH than in NAFL. IL-6 expression levels were significantly higher in NASH than in NAFL and showed a positive correlation with FUT6 expression levels. The serum-AAT-A3F levels strongly correlated with hepatic FUT6 expression levels. AAT-A3F levels increased with fibrosis, pathological inflammation, and ballooning in patients with NAFLD and may be useful for non-invasive diagnosis of NASH from the early stages of fibrosis. - C型肝炎患者の血清Angiopoietin-2値はDAAs治療後の肝線維化非改善例を予測する
川岸 直樹; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 60, Suppl.2, A653, A653, (一社)日本肝臓学会, Oct. 2019, [Peer-reviewed]
Japanese - カルニチンは肝硬変患者における筋肉量減少を抑制する
大原 正嗣; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 川岸 直樹; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 60, Suppl.2, A677, A677, (一社)日本肝臓学会, Oct. 2019, [Peer-reviewed]
Japanese - 進行肝細胞癌に対するレンバチニブ投与症例からみた適格使用時期の検討
荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉
肝臓, 60, Suppl.2, A705, A705, (一社)日本肝臓学会, Oct. 2019, [Peer-reviewed]
Japanese - Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of α2,3-Linked Sialic Acid Residues.
Hanamatsu H; Nishikaze T; Tsumoto H; Ogawa K; Kobayashi T; Yokota I; Morikawa K; Suda G; Sho T; Nakai M; Miura N; Higashino K; Sekiya S; Iwamoto S; Miura Y; Furukawa JI; Tanaka K; Sakamoto N
Analytical chemistry, 91, 21, 13343, 13348, Oct. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, Sialic acids form the terminal sugars in glycan chains on glycoproteins via α2,3, α2,6, or α2,8 linkages, and structural isomers of sialyl linkages play various functional roles in cell recognition and other physiological processes. We recently developed a novel procedure based on sialic acid linkage-specific alkylamidation via lactone ring opening (aminolysis-SALSA). Herein, we have investigated an isotope labeling of α2,3-linked sialic acid residues (iSALSA) using amine hydrochloride salts. One limitation of SALSA using amine hydrochloride salts may be solved by adding only tert-butylamine (t-BA) as an acid scavenger, and comparative and quantitative glycomic analyses can be performed using iSALSA. We also developed quantitative glycomic analysis using dual isotope-labeled glycans by derivatizing with aminooxy-functionalized tryptophanylarginine methyl ester (aoWR) and iSALSA at the reducing and nonreducing end, respectively. Furthermore, we demonstrate that the amount of α2,3-linked sialoglycans in serum are altered during liver fibrosis using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) and liquid chromatography MS (LC/MS) analyses. We revealed that the ratio of A33,6,6 to A3F3,6,6 was gradually decreased along with liver fibrosis progression. Therefore, these glycan alterations are potential diagnostic markers of nonalcoholic steatohepatitis (NASH) fibrosis progression. - Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
Suzuki K; Suda G; Yamamoto Y; Furuya K; Baba M; Kimura M; Maehara O; Shimazaki T; Yamamoto K; Shigesawa T; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
Hepatology research : the official journal of the Japan Society of Hepatology, 49, 11, 1294, 1304, Wiley, Jul. 2019, [Peer-reviewed]
Scientific journal - Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs.
Suda G; Kimura M; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Maehara O; Shimazaki T; Morikawa K; Natsuizaka M; Ogawa K; Sakamoto N
Hepatology research : the official journal of the Japan Society of Hepatology, 49, 11, 1275, 1285, Wiley, Jul. 2019, [Peer-reviewed]
Scientific journal - Correlation between Liver Elasticity by Ultrasound Elastography and Liver Functional Reserve.
Sugiura R; Kuwatani M; Nishida M; Hirata K; Sano I; Kato S; Kawakubo K; Nakai M; Sho T; Suda G; Morikawa K; Ogawa K; Sakamoto N
Ultrasound in medicine & biology, Jul. 2019, [Peer-reviewed] - Quantifying Protein-Specific N-glycome Profiles by Focused Protein- and Immunoprecipitation-Glycomics.
Kobayashi T; Ogawa K; Furukawa JI; Hanamatsu H; Hato M; Yoshinaga T; Morikawa K; Suda G; Sho T; Nakai M; Higashi-No K; Numata Y; Shinohara Y; Sakamoto N
Journal of proteome research, Jul. 2019, [Peer-reviewed] - Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
Izumi T; Sho T; Morikawa K; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Umemura M; Shimazaki T; Kimura M; Nakai M; Suda G; Natsuizaka M; Ogawa K; Kudo Y; Nishida M; Ono K; Baba M; Furuya K; Sakamoto N
Hepatology research : the official journal of the Japan Society of Hepatology, 49, 10, 1207, 1217, Wiley, Jun. 2019, [Peer-reviewed]
Scientific journal - Long-term effect of nucleos (t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients
Morikawa Kenichi; Umemura Machiko; Ogawa Koji; Shigesawa Taku; Suzuki Kazuharu; Nakamura Akihisa; Ohara Masatsugu; Kawagishi Naoki; Shimazaki Tomoe; Kimura Megumi; Izumi Takaaki; Nakai Masato; Sho Takuya; Suda Goki; Natsuizaka Mitsuteru; Ono Kota; Murata Kazumoto; Sugiyama Masaya; Masashi Mizokami; Sakamoto Naoya
JOURNAL OF HEPATOLOGY, 70, E477, Apr. 2019, [Peer-reviewed] - The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Suda G; Nakai M; Sho T; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Baba M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
Internal medicine (Tokyo, Japan), 58, 7, 943, 947, Japanese Society of Internal Medicine, Apr. 2019, [Peer-reviewed]
Scientific journal - Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
Journal of gastroenterology, 54, 7, 641, 649, 18 Feb. 2019, [Peer-reviewed]
Japanese, Scientific journal - Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay
Koji Ogawa; Kazuharu Suzuki; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Naoya Sakamoto
Acta Hepatologica Japonica, 60, 11, 397, 404, Japan Society of Hepatology, 2019
Japanese, Scientific journal - Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
Suda G; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Hasebe C; Abe M; Haga H; Ueno Y; Masakane I; Abe K; Takahashi A; Ohira H; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Kawakami A; Kumagai K; Terasita K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
Journal of gastroenterology, 54, 1, 78, 86, Jan. 2019, [Peer-reviewed] - Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
Sho T; Suda G; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Izumi T; Kawagishi N; Baba M; Nakai M; Natsuizka M; Morikawa K; Ogawa K; Sakamoto N; NORTE Study Group
Internal medicine (Tokyo, Japan), 58, 6, 797, 802, Nov. 2018, [Peer-reviewed] - Higher Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (M2BPGi) Not M2BP and Pre-Sarcopenia Are Prognostic and Recurrence Markers of Primary Hepatocellular Carcinoma Treated By RFA in HCV-Negative and HCV-Eradicated Patients.
Nakai Masato; Suda Goki; Ogawa Koji; Suzuki Kazuharu; Nakamura Akihisa; Ohara Masatsugu; Kawagishi Naoki; Umemura Machiko; Sho Takuya; Morikawa Kenichi; Sakamoto Naoya
HEPATOLOGY, 68, 843A, 844A, Oct. 2018, [Peer-reviewed] - L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
Ohara M; Ogawa K; Suda G; Kimura M; Maehara O; Shimazaki T; Suzuki K; Nakamura A; Umemura M; Izumi T; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ohnishi S; Sakamoto N
Hepatology communications, 2, 8, 906, 918, Wiley, Aug. 2018, [Peer-reviewed]
Scientific journal - Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
Takuya Sho; Goki Suda; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Kenichi Kumagai; Minoru Uebayashi; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Manabu Onodera; Takashi Meguro; Megumi Kimura; Jun Ito; Machiko Umemura; Takaaki Izumi; Naoki Kawagishi; Masatsugu Ohara; Yuji Ono; Masato Nakai; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 48, 7, 529, 538, Jun. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, AIM: The safety and efficacy of sofosbuvir (SOF) and ribavirin (RBV) have not been well clarified in patients with renal dysfunction because clinical trials have not included such patients. We evaluated the safety and efficacy of SOF and RBV for genotype 2 hepatitis C virus (HCV)-infected patients with renal dysfunction. METHODS: The study included genotype 2 HCV-infected patients who received SOF and RBV between July 2014 and May 2017. The sustained virologic response (SVR) after the treatment and safety during the therapy were evaluated according to renal function. RESULTS: A total of 231 patients were included in this study. The median age was 62 years old, and 45.9% (106/231) were men. Of the 231 patients, 191 (82.8%) and 40 (17.2%) were classified as having chronic kidney disease (CKD) stages G1/2 and G3, respectively. The overall SVR rate was 97% (224/231). The SVR rates in patients with CKD stages G1, 2, G3a, and G3b were 98.1%, 98.6%, 87.9%, and 100%, respectively, and this therapy was tolerated. Multivariate analysis indicated that renal dysfunction was significantly associated with a non-SVR (odds ratio, 6.963; 95% confidence interval, 1.494-32.41; P = 0.013). The patients with renal dysfunction were older, had advanced liver fibrosis, lower baseline platelet and hemoglobin levels, and a higher rate of RBV dose reduction. CONCLUSIONS: Sofosbuvir and RBV therapy is highly effective and safe for genotype 2 HCV-infected Japanese patients. However, attention should be paid to baseline renal function when SOF- and RBV-containing regimens are used for patients with renal dysfunction. - Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
Goki Suda; Jun Ito; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Munenori Okamoto; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Junichi Yoshida; Takashi Meguro; Masatsugu Ohara; Naoki Kawagishi; Megumi Kimura; Machiko Umemura; Takaaki Izumi; Yoko Tsukuda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 48, 3, E146-E154, E154, Feb. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: The Japan Society of Hepatology guidelines indicate that hepatitis C virus (HCV) protease inhibitor combination therapy with simeprevir (SMV), pegylated-interferon (Peg-IFN), and ribavirin (RBV) is a therapeutic option for patients who fail to respond to a direct direct-acting antiviral-containing regimen. However, treatment outcomes have room for improvement. Fluvastatin (FLV) add-on treatment in Peg-IFN and RBV combination therapy for HCV-infected patients significantly improved the sustained virologic response (SVR), but the add-on effect of FLV on SMV combination therapy is not well understood. METHODS: This was a prospective, randomized, multicenter study in which a total of 61 HCV genotype 1b-infected patients were recruited and 60 eligible patients were randomly allocated to two groups that received 12 weeks of SMV/Peg-IFN/RBV followed by 12 weeks of Peg-IFN/RBV with or without 24 weeks of FLV. The SVR rate and adverse events were compared between the two groups. RESULTS: Thirty-one patients were allocated to the FLV add-on group and 29 patients were allocated to the control group. Baseline clinical factors, including median age, baseline platelet count, alanine aminotransferase level, HCV RNA titer, Fibrosis-4 index, and rate of IL28B minor genotype, were all similar between the two groups. The rapid virologic response, end-of-treatment response rates, SVR rates at 24 weeks after treatment, and safety profiles were also similar between the two groups. CONCLUSIONS: This prospective, randomized, multicenter study indicated that FLV had no add-on effect when given with SMV/Peg-IFN/RBV combination therapy for genotype 1b HCV-infected patients. - Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
Masato Nakai; Koji Ogawa; Rei Takeda; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Machiko Umemura; Jun Ito; Takuya Sho; Goki Suda; Kenichi Morikawa; Naoya Sakamoto
Hepatology research : the official journal of the Japan Society of Hepatology, 48, 3, E311-E319, E319, Feb. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, AIM: Water retention, hepatic ascites, and peripheral edema are significant problems in patients with liver cirrhosis (LC). Although furosemide and spironolactone are commonly used as treatment, they are often insufficient to treat hyponatremia and renal insufficiency in patients with LC. Tolvaptan (TVP) could provide an effective treatment alternative. However, predictive factors of a therapeutic response to TVP are unclear. Our aim was to examine clinical predictors of the response to TVP in patients with LC and water retention. METHODS: Fifty-two patients were treated with TVP, with therapeutic effects judged by a decrease in body weight (≥2 kg) and increase in urinary volume (≥500 mL) within 7 days. Blood biochemical tests were carried out at baseline and post-treatment, including serum soluble CD14 (sCD14) and urinary aquaporin 2 (AQP2) levels. Clinical and laboratory predictive factors of a TVP response were evaluated by univariate and multivariate analyses. RESULTS: The overall response to TVP was 55.8%. On univariate analyses, serum C-reactive protein (CRP) level, the neutrophil-to-lymphocyte ratio, urinary blood urea nitrogen, and urinary AQP2 were predictors of the TVP response, with only serum CRP retained on multivariate analysis. A higher serum sCD14 level was strongly associated with a non-response to TVP. A decrease in urinary AQP2 to undetectable level was associated with a response. CONCLUSION: Tolvaptan provides a rapid and strong effect to improve water retention in patients with LC. Baseline serum sCD14 and CRP levels are useful predictors of a response to TVP, with a decrease in urinary AQP2 during treatment indicating an early response. - Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PloS one, 13, 12, e0209615, e0209615, Public Library of Science (PLoS), 2018, [Peer-reviewed]
Scientific journal - Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Goki Suda; Norihiro Furusyo; Hidenori Toyoda; Yoshiiku Kawakami; Hiroki Ikeda; Michihiro Suzuki; Keiko Arataki; Nami Mori; Keiji Tsuji; Yoshio Katamura; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Noritomo Shimada; Atsushi Hiraoka; Sho Yamsaki; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Mineo Kudo; Atsushi Nagasaka; Ken Furuya; Yoshiya Yamamoto; Kanji Kato; Yoshiyuki Ueno; Etsuko Iio; Yasuhito Tanaka; Masayuki Kurosaki; Takashi Kumada; Kazuaki Chayama; Naoya Sakamoto
Journal of gastroenterology, 53, 1, 119, 128, Jan. 2018, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, BACKGROUND: Hepatitis C virus (HCV) infection is common in hemodialysis patients and worsens their prognosis, while antiviral therapy options are limited. Recently, clinical trial and real-world, small-scale studies have reported excellent responses to direct-acting antivirals in patients with advanced chronic kidney diseases. However, real-world, large-scale data were lacking. This large multicenter analysis included HCV-infected hemodialysis patients receiving combination therapy with a nonstructural protein 5A (NS5A) inhibitor, daclatasvir (DCV), and a protease inhibitor, asunaprevir (ASV). METHODS: Twenty-three centers in Japan participated in this study of 123 hemodialysis patients with genotype 1 HCV infection, who received DCV/ASV combination therapy between November 2014 and March 2016. We collected and analyzed data relating to treatment outcome, baseline clinical information, laboratory measurements (during and after the treatment), and adverse events. RESULTS: Thirty-nine patients (31.7%) had advanced liver fibrosis, 12 (9.8%) had histories of hepatocellular carcinoma (HCC), and 18 (14.6%) had baseline resistance-associated variants (RAVs) of NS5A. The overall sustained virological response (SVR)12 rate was 95.9% (118/123). Notably, all patients with HCC and 94.4% (17/18) of those with NS5A RAVs achieved SVR12. Significant factors associated with non-SVR were advanced fibrosis and the interleukin-28B non-TT genotype at rs8099917. Four patients (3.3%) discontinued therapy because of adverse events including elevated serum alanine transaminase levels (n = 2), rash (n = 1), and HCC (n = 1); all of these achieved SVR12. CONCLUSIONS: This real-world, nationwide study revealed that DCV/ASV combination therapy was safe and highly effective for hemodialysis patients with genotype 1 HCV infections. This study was registered at the UMIN Clinical Trials Registry (UMIN000024227). - Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection
Naoki Kawagishi; Goki Suda; Masahiro Onozawa; Megumi Kimura; Osamu Maehara; Jun Ito; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
JOURNAL OF HEPATOLOGY, 67, 5, 1106, 1108, Nov. 2017, [Peer-reviewed]
English - Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma
Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A. Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
CARCINOGENESIS, 38, 11, 1073, 1083, Nov. 2017, [Peer-reviewed]
English, Scientific journal - Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment
Goki Suda; Atsushi Nagasaka; Yoshiya Yamamoto; Ken Furuya; Kenichi Kumagai; Mineo Kudo; Katsumi Terashita; Tomoe Kobayashi; Izumi Tsunematsu; Junichi Yoshida; Takashi Meguro; Megumi Kimura; Jun Ito; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Yoko Tsukuda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
HEPATOLOGY RESEARCH, 47, 11, 1127, 1136, Oct. 2017, [Peer-reviewed]
English, Scientific journal - Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy
Goki Suda; Koji Ogawa; Yoshiya Yamamoto; Masaki Katagiri; Ken Furuya; Kenichi Kumagai; Jun Konno; Megumi Kimura; Naoki Kawagishi; Masatsugu Ohara; Machiko Umemura; Jun Ito; Takaaki Izumi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Akihito Tsubota; Noritomo Shimada; Etsuko Iio; Yasuhito Tanaka; Naoya Sakamoto
JOURNAL OF GASTROENTEROLOGY, 52, 10, 1122, 1129, Oct. 2017, [Peer-reviewed]
English, Scientific journal - A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
Takuya Sho; Mitsuru Nakanishi; Kenichi Morikawa; Masatsugu Ohara; Naoki Kawagishi; Takaaki Izumi; Machiko Umemura; Jun Ito; Masato Nakai; Goki Suda; Koji Ogawa; Makoto Chuma; Takashi Meguro; Michio Nakamura; Atsushi Nagasaka; Hiromasa Horimoto; Yoshiya Yamamoto; Naoya Sakamoto
Drugs in R&D, 17, 3, 381, 388, Sep. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND AND AIMS: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive anticancer activity. The purpose of this phase I study was to investigate the safety and tolerability of combination therapy with sorafenib and 5-fluorouracil (5-FU) and to determine the optimum dose of 5-FU for a phase II trial. METHODS: This phase I study used a conventional 3 + 3 dose-escalation design. The primary endpoint was to determine the maximum tolerated dose (MTD) of 5-FU in combination with sorafenib and to determine the recommended dosage (RD) for phase II. The secondary endpoints evaluated were toxicity and the tumor response rate. All patients received 800 mg of sorafenib daily and three different dosages of 5-FU (250, 350, and 450 mg/m2/day) for 20 days by intravenous infusion in 1 month as one cycle. RESULTS: Twelve patients with advanced HCC were evaluated. The MTD of 5-FU in combination with sorafenib was 450 mg/m2/day, and 350 mg/m2/day was selected as the RD for a phase II study. Thrombocytopenia, stomatitis, and hand-foot skin reaction were observed as grade 3 adverse events. Nine patients achieved stable disease (75%), and three patients (25%) were judged to have progressive disease. The disease control rate was 75%. CONCLUSIONS: Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential to be an option for advanced HCC. - Combination of neutrophil-to-lymphocyte ratio and early des--carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma
Seiji Tsunematsu; Goki Suda; Kazushi Yamasaki; Megumi Kimura; Izumi Takaaki; Machiko Umemura; Jun Ito; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Toshiya Kamiyama; Akinobu Taketomi; Naoya Sakamoto
HEPATOLOGY RESEARCH, 47, 6, 533, 541, May 2017, [Peer-reviewed]
English, Scientific journal - Anti-Adipogenic and Antiviral Effects of L-Carnitine on Hepatitis C Virus Infection
Yoko Tsukuda; Goki Suda; Seiji Tsunematsu; Jun Ito; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Takuya Sho; Osamu Maehara; Tomoe Shimazaki; Megumi Kimura; Kenichi Morikawa; Mitsuteru Natsuizaka; Koji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Naoya Sakamoto
JOURNAL OF MEDICAL VIROLOGY, 89, 5, 857, 866, May 2017, [Peer-reviewed]
English, Scientific journal - Hepatitis B virus Xprotein impairs alpha-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protzin phosphatase 2A
Seiji Tsunematsu; Goki Suda; Kazushi Yamasaki; Megumi Kimura; Takaaki Izumi; Machiko Umemura; Jun Ito; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Yasuhito Tanaka; Koichi Watashi; Takaji Wakita; Naoya Sakamoto
JOURNAL OF MEDICAL VIROLOGY, 89, 2, 267, 275, Feb. 2017, [Peer-reviewed]
English, Scientific journal - Investigation of the utility of various diagnostic guidelines for Wilson's disease.
Nakai M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Tsunematsu S; Sato F; Sho T; Suda G; Ogawa K; Sakamoto N
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 114, 5, 839, 845, 2017, [Peer-reviewed] - Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
Goki Suda; Koji Ogawa; Megumi Kimura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
Journal of clinical and translational hepatology, 4, 4, 320, 327, 28 Dec. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, Prevalence of hepatitis C virus (HCV) infection is high in patients with end-stage renal dysfunction, including patients undergoing hemodialysis (HD). The HCV infection itself can cause glomerulonephritis and puts individuals at increased risk of developing end-stage renal disease; fortunately, successful HCV eradication sometimes restore HCV-related renal dysfunction. Moreover, the prognosis of dialysis patients infected with HCV is significantly worse and the renal allograft survival in HCV-infected patients is also worse than in dialysis patients without HCV infection. If life prognosis is favorable, therefore, anti-HCV therapy is strongly recommended for HCV-infected patients with severe renal dysfunction. The standard therapy for HCV-infected patients with severe renal dysfunction has historically been interferon-based therapy. However, this therapy remains ineffective in achieving high, sustained viral response rates and the rate of adverse events and treatment discontinuation due to treatment-induced adverse events continues to be high in patients with severe renal dysfunction. Safe and effective anti-HCV therapies are urgently needed, and crucial, for patients with severe renal dysfunction. Recently, direct-acting antivirals (DAAs) that specifically target viral proteins have been developed, and these targets include the NS3, NS5A, and NS5B of HCV. Clinical trials have revealed high efficacy and safety of the DAA-based therapies, but patients with severe renal dysfunction were not included in the majority of these trials. However, several recent reports have shown high efficacy and safety for some regimens of DAA combination therapy for HCV-infected patients with severe renal dysfunction. In this review, we discuss novel treatments for HCV-infected patients with severe renal dysfunction and the pharmacokinetics of these drugs. - Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection
Jun Ito; Goki Suda; Yoshiya Yamamoto; Atsushi Nagasaka; Ken Furuya; Kenichi Kumagai; Hideaki Kikuchi; Takuto Miyagishima; Tomoe Kobayashi; Megumi Kimura; Kazushi Yamasaki; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
HEPATOLOGY RESEARCH, 46, 13, 1294, 1303, Dec. 2016, [Peer-reviewed]
English, Scientific journal - Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
Goki Suda; Mineo Kudo; Atsushi Nagasaka; Ken Furuya; Yoshiya Yamamoto; Tomoe Kobayashi; Keisuke Shinada; Miki Tateyama; Jun Konno; Yoko Tsukuda; Kazushi Yamasaki; Megumi Kimura; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
JOURNAL OF GASTROENTEROLOGY, 51, 7, 733, 740, Jul. 2016, [Peer-reviewed]
English, Scientific journal - The decreased urinary aquaporin2 excretion is a predictive factor for the efficacy of Tolvaptan in patients with hepatic cirrhosis
Nakai Masato; Itoh Jun; Sato Fumiyuki; Tsunematsu Seiji; Sho Takuya; Suda Goki; Morikawa Kenichi; Ogawa Koji; Sakamoto Naoya
HEPATOLOGY, 62, 358A, Oct. 2015, [Peer-reviewed] - A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma
Osamu Maehara; Fumiyuki Sato; Mitsuteru Natsuizaka; Ayaka Asano; Yoshimasa Kubota; Jun Itoh; Seiji Tsunematsu; Katsumi Terashita; Yoko Tsukuda; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Koji Ogawa; Makoto Chuma; Koji Nakagawa; Shunsuke Ohnishi; Yoshito Komatsu; Kelly A. Whelan; Hiroshi Nakagawa; Hiroshi Takeda; Naoya Sakamoto
CANCER BIOLOGY & THERAPY, 16, 10, 1453, 1461, Oct. 2015, [Peer-reviewed]
English, Scientific journal - Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions
Goki Suda; Yoshiya Yamamoto; Astushi Nagasaka; Ken Furuya; Mineo Kudo; Yoshimichi Chuganji; Yoko Tsukuda; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terasita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kouji Ogawa; Shunsuke Ohnishi; Makoto Chuma; Yasuyuki Fujita; Riichiro Abe; Miki Taniguchi; Mina Nakagawa; Yasuhiro Asahina; Naoya Sakamoto
HEPATOLOGY RESEARCH, 45, 8, 837, 845, Aug. 2015, [Peer-reviewed]
English, Scientific journal - Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma
Seiji Tsunematsu; Makoto Chuma; Toshiya Kamiyama; Noriyuki Miyamoto; Satoshi Yabusaki; Kanako Hatanaka; Tomoko Mitsuhashi; Hirofumi Kamachi; Hideki Yokoo; Tatsuhiko Kakisaka; Yousuke Tsuruga; Tatsuya Orimo; Kenji Wakayama; Jun Ito; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Yoko Tsukuda; Takuya Sho; Goki Suda; Kenichi Morikawa; Mitsuteru Natsuizaka; Mitsuru Nakanishi; Koji Ogawa; Akinobu Taketomi; Yoshihiro Matsuno; Naoya Sakamoto
ABDOMINAL IMAGING, 40, 6, 1492, 1499, Aug. 2015, [Peer-reviewed]
English, Scientific journal - KLF5 Promotes Tumorigenicity of Hepatocellular Carcinoma by Upregulation of Cancer Stem-Like Cells
Sato Fumiyuki; Natsuizaka Mitsuteru; Maehara Osamu; Asano Ayaka; Kubota Yoshimasa; Itoh Jun; Tsunematsu Seiji; Tsukuda Yoko; Terashita Katsumi; Nakai Masato; Sho Takuya; Suda Goki; Morikawa Kenichi; Ogawa Koji; Ohnishi Shunsuke; Sakamoto Naoya
GASTROENTEROLOGY, 148, 4, S43, Apr. 2015, [Peer-reviewed] - Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-B/mitogen-activated protein kinase
Makoto Chuma; Naoya Sakamoto; Akira Nakai; Shuhei Hige; Mitsuru Nakanishi; Mitsuteru Natsuizaka; Goki Suda; Takuya Sho; Kanako Hatanaka; Yoshihiro Matsuno; Hideki Yokoo; Toshiya Kamiyama; Akinobu Taketomi; Gen Fujii; Kosuke Tashiro; Yoko Hikiba; Mitsuaki Fujimoto; Masahiro Asaka; Shin Maeda
CARCINOGENESIS, 35, 2, 272, 281, Feb. 2014, [Peer-reviewed]
English, Scientific journal - A pivotal role of KLF5 in regulation of cancer stem-like cells in hepatocellular carcinoma
Mitsuteru Natsuizaka; Osamu Maehara; Fumiyuki Sato; Yoshimasa Kubota; Goki Suda; Jun Itoh; Seiji Tsunematsu; Yoko Tsukuda; Katsumi Terashita; Masato Nakai; Takuya Sho; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
HEPATOLOGY, 60, 825A, 825A, 2014, [Peer-reviewed]
English - Characterization of a lymphotropic HCV-J6JFH1 replication in human primary B cells
Nakai Masato; Seya Tsukasa; Matsumoto Misako; Aly Hussein H; Itoh Jun; Tsunematsu Seiji; Sato Fumiyuki; Tsukuda Yoko; Terashita Katsumi; Sho Takuya; Suda Goki; Natsuizaka Mitsuteru; Ogawa Koji; Sakamoto Naoya
HEPATOLOGY, 60, 1083A, 1084A, 2014, [Peer-reviewed] - Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus
Seiji Tsunematsu; Mitsuteru Natsuizaka; Hiromi Fujita; Noriyuki Otsuka; Katsumi Terashita; Fumiyuki Sato; Tomoe Kobayashi; Masato Nakai; Yoko Tsukuda; Hiromasa Horimoto; Takuya Sho; Goki Suda; Mitsuru Nakanishi; Satoshi Hashino; Makoto Chuma; Naoya Sakamoto
INTERNAL MEDICINE, 53, 18, 2079, 2082, 2014, [Peer-reviewed]
English, Scientific journal - Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C
Tomoe Kobayashi; Shuhei Hige; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Koji Ogawa; Makoto Chuma; Naoya Sakamoto; Masahiro Asaka
JOURNAL OF GASTROENTEROLOGY, 47, 11, 1228, 1237, Nov. 2012, [Peer-reviewed]
English, Scientific journal - Efficacy of therapy for advanced hepatocellular carcinoma: Intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation
Makoto Chuma; Hiroshi Taguchi; Yoshiya Yamamoto; Shinichi Shimizu; Mitsuru Nakanishi; Koji Ogawa; Takuya Sho; Hiromasa Horimoto; Tomoe Kobayashi; Masato Nakai; Katsumi Terashita; Yusuke Sakuhara; Daisuke Abo; Yoko Tsukuda; Seiji Tsunematsu; Shuhei Hige; Mototsugu Kato; Hiroki Shirato; Masahiro Asaka
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26, 7, 1123, 1132, Jul. 2011, [Peer-reviewed]
English, Scientific journal - TRIM29 negatively regulates p53 via inhibition of Tip60
Takuya Sho; Tadasuke Tsukiyama; Tomonobu Sato; Takeshi Kondo; Jun Cheng; Takashi Saku; Masahiro Asaka; Shigetsugu Hatakeyama
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1813, 6, 1245, 1253, Jun. 2011, [Peer-reviewed]
English, Scientific journal - TRIM29 negatively regulates p53 via inhibition of Tip60.
Sho T; Tsukiyama T; Sato T; Kondo T; Cheng J; Saku T; Asaka M; Hatakeyama S
Biochimica et biophysica acta, 1813, 6, 1245, 1253, Jun. 2011, [Peer-reviewed] - [Interferon therapy for chronic hepatitis B].
Hige S; Sho T; Nakanishi M; Chuma M
Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 4, 481, 485, May 2011, [Peer-reviewed] - RNF43 interacts with NEDL1 and regulates p53-mediated transcription
Keisuke Shinada; Tadasuke Tsukiyama; Takuya Sho; Fumihiko Okumura; Masahiro Asaka; Shigetsugu Hatakeyama
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 404, 1, 143, 147, Jan. 2011, [Peer-reviewed]
English, Scientific journal - Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids
Shuhei Hige; Yoichi Yamamoto; Shigeru Yoshida; Tomoe Kobayashi; Hiromasa Horimoto; Keiko Yamamoto; Takuya Sho; Mitsuteru Natsuizaka; Mitsuru Nakanishi; Makoto Chuma; Masahiro Asaka
JOURNAL OF CLINICAL MICROBIOLOGY, 48, 12, 4487, 4494, Dec. 2010, [Peer-reviewed]
English, Scientific journal - The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma
Makoto Chuma; Shuhei Hige; Toshiya Kamiyama; Takashi Meguro; Atsushi Nagasaka; Kazuaki Nakanishi; Yoshiya Yamamoto; Mitsuru Nakanishi; Toshihisa Kohara; Takuya Sho; Keiko Yamamoto; Hiromasa Horimoto; Tomoe Kobayashi; Hideki Yokoo; Michiaki Matsushita; Satoru Todo; Masahiro Asaka
JOURNAL OF GASTROENTEROLOGY, 44, 9, 991, 999, Sep. 2009, [Peer-reviewed]
English, Scientific journal
- アテゾリズマブ+ベバシズマブ治療によるConversion前後の肝予備能および蛋白尿の変化
荘拓也; 須田剛生; 北野翔一; 目野晃光; 保浦直弘; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 33rd, 2026 - 切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の長期成績と予後因子に関する検討:North Japan多施設共同研究
阿部珠美; 黒田英克; 二宮匡史; 荘拓也; 須田剛生; 及川隆喜; 飯野勢; 沼尾宏; 佐藤亘; 田邊暢一; 勝見智大; 阿部和道; 山本義也; 馬場英; 目黒高志; 松本主之; 坂本直哉; 上野義之, 日本肝がん分子標的治療研究会プログラム・抄録集, 33rd, 2026 - 切除不能進行肝細胞癌におけるアテゾリズマブ+ベバシズマブ併用療法の治療効果とTACE併用療法の意義
荘拓也; 須田剛生; 田中崇倫; 北野翔一; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 32nd, 2025 - 慢性B型肝炎症例におけるCAMP-BとPAGE-Bによる発癌リスク評価の検討
大原正嗣; 須田剛生; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 坂本直哉, 日本消化器病学会雑誌(Web), 122, 2025 - High-flow hemodiafiltration時代の急性肝不全診療
川村典生; 嶋村剛; 後藤了一; 巖築慶一; 渡辺正明; 中井正人; 荘拓也; 森川賢一; 小川浩司; 武冨紹信; 武冨紹信, 肝臓, 65, 5, 2024 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の早期治療効果と安全性
荘拓也; 須田剛生; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 29th, 2024 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の治療効果と安全性の検討
荘拓也; 須田剛生; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 細田峻一; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 小川浩司; 馬場英; 高木智史; 目黒高志; 吉田苑永; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 30th, 2024 - The role of contrast-enhanced US in determining the therapeutic effect of LEN-TACE therapy
荘拓也; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 超音波医学 Supplement, 51, 2024 - 門脈圧亢進症合併HCV症例のSVR後の肝予備能,非代償化の検討
中井正人; 大原正嗣; 北潟谷隆; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024 - Efficacy and safety of durvalumab and tremelimumab for advanced hepatocellular carcinoma
荘拓也; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 得地祐匡; 山本義也; 坂本直哉, 肝胆膵, 89, 3, 2024 - 高齢肝疾患患者における筋肉量評価法の検討
大原正嗣; 須田剛生; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 細田峻一; 吉田苑永; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 慢性肝疾患患者の低栄養アセスメントを行うべき患者を適切に絞り込むスクリーニング方法の検討
中井正人; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 小川浩司; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 進行肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績
荘拓也; 須田剛生; 吉田苑永; 細田峻一; 北潟谷隆; 大原正嗣; 中井正人; 小川浩司; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 馬場英; 高木智史; 目黒高志; 山本義也; 坂本直哉, 肝臓, 65, Supplement 1, 2024 - 北海道における肝炎ウイルス陽性者対策の課題
大原正嗣; 小川浩司; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 中井正人; 荘拓也; 須田剛生; 坂本直哉, 肝臓, 65, Supplement 2, 2024 - 切除不能肝細胞癌に対するレンバチニブ治療後のFGF21の変化と食欲不振の関連性について
甲谷理紗子; 須田剛生; 大原正嗣; 佐々木貴志; 吉田苑永; 細田峻一; 北潟谷隆; 中井正人; 荘拓也; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 121, 2024 - 進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法中に自己免疫性脳炎を発症した1例
北野翔一; 荘拓也; 保浦直弘; 目野晃光; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 須田剛生; 坂本直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135th-129th, 2024 - 門脈圧亢進症症例における低栄養と適切なスクリーニング方法の検討
中井正人; 北野翔一; 田中崇倫; 目野晃光; 保浦直弘; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 荘拓也; 須田剛生; 坂本直哉, 日本門脈圧亢進症学会雑誌, 30, 3 (CD-ROM), 2024 - 切除不能進行肝細胞癌におけるICI-Rechallenge療法の治療効果と安全性の検討
荘拓也; 須田剛生; 甲谷理紗子; 佐々木貴志; 北潟谷隆; 大原正嗣; 中井正人; 山田錬; 佃曜子; 小林智絵; 川岸直樹; 小川浩司; 高木智史; 目黒高志; 馬場英; 山本義也; 坂本直哉, 日本肝がん分子標的治療研究会プログラム・抄録集, 31st, 2024 - IMbrave150基準外症例におけるアテゾリズマブ+ベバシズマブ併用療法の生存に寄与する因子の検討-多施設共同研究-
荘拓也; 須田剛生; 大原正嗣; 中井正人; 小川浩司; 出水孝章; 目黒高志; 中村晃久; 高木智史; 馬場英; 古家乾; 山本義也; 伊藤淳; 山田錬; 宮城島拓人; 坂本直哉, 日本消化器病学会雑誌(Web), 120, 2023 - 核酸アナログによるHBs抗原消失—Hepatitis B surface antigen (HBsAg) seroclearance by nucleos(t)ide analogs treatment—特集 B型肝炎診療の進歩
山田 錬; 森川 賢一; 中村 晃久; 出水 孝章; 梅村 真知子; 大原 正嗣; 中井 正人; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編, 12, 2, 184, 192, Aug. 2022
科学評論社, Japanese - B型肝炎治療オーバービュー—Overview of treatment for hepatitis B—特集 B型肝炎診療の進歩
須田 剛生; 川岸 直樹; 大原 正嗣; 中井 正人; 荘 拓也; 小川 浩司; 坂本 直哉, 消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編, 12, 2, 172, 174, Aug. 2022
科学評論社, Japanese - 減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する
中村 昭伸; 大江 悠希; 久住 麻唯子; 宮 愛香; 野本 博司; 亀田 啓; 曹 圭龍; 小川 浩司; 荘 拓也; 須田 剛生; 吉川 仁人; 阿保 大介; 西田 睦; 海老原 裕磨; 倉島 庸; 工藤 與亮; 坂本 直哉; 平野 聡; 渥美 達也; 三好 秀明, 糖尿病, 65, Suppl.1, S, 153, Apr. 2022
(一社)日本糖尿病学会, Japanese - 肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である
大原正嗣; 須田剛生; 重沢拓; 鈴木和治; 中村晃久; 川岸直樹; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 62, Supplement 1, 2021 - Intrahepatic arterio-venous shunt
小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 日本臨床, 2021 - トルバプタン奏効後の再燃と炎症および尿L-FABP値の関連
中井正人; 北潟谷隆; 山田錬; 重沢拓; 鈴木和治; 中村晃久; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 1, 2020 - 肝性脳症の疫学
中井正人; 小川浩司; 久保彰則; 得地祐匡; 北潟谷隆; 山田錬; 重沢拓; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 日本門脈圧亢進症学会雑誌, 26, 3, 2020 - HCC既往の無いC型肝炎SVR後の初発肝発癌の囲い込み因子としての肝弾性度の有用性
中井正人; 山本義也; 馬場英; 古家乾; 北潟谷隆; 山田錬; 重沢拓; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 2, 2020 - 免疫チェックポイント阻害剤関連肝炎の頻度,予測因子,臨床経過の検討
北潟谷隆; 須田剛生; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 61, Supplement 2, 2020 - Comparative Glycomic Analysis by Aminolysis-SALSA method combined with Sialyl Linkage-specific Isotope Labeling.
花松久寿; 西風隆司; 津元裕樹; 小川浩司; 横田育子; 森川賢一; 須田剛生; 荘拓也; 中井正人; 三浦信明; 関谷禎規; 岩本慎一; 三浦ゆり; 田中耕一; 坂本直哉; 古川潤一, 日本糖質学会年会要旨集, 39th, 2020 - 【肝胆膵の線維化up-to-date】肝臓の線維化 臨床・病理 新たな肝線維化マーカーの開発状況
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 79, 5, 891, 896, Nov. 2019
(株)アークメディア, Japanese - CLIA法を用いたPIVKA-IIの臨床的有用性の評価
小川 浩司; 鈴木 和治; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 60, 11, 397, 404, Nov. 2019
(一社)日本肝臓学会, Japanese - 進行肝細胞癌に対するレンバチニブの奏功に寄与する因子と予備能変化についての検討
山田 錬; 荘 拓也; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 60, Suppl.3, A946, A946, Nov. 2019
(一社)日本肝臓学会, Japanese - TRI-ANTENNARY TRI-SIALYLATED MONO-FUCOSYLATED GLYCAN OF ALPHA-1 ANTITRYPSIN AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS
Takashi Kobayashi; Koji Ogawa; Jun-Ichi Furukawa; Hisatoshi Hanamatsu; Masato Nakai; Takuya Sho; Goki Suda; Kenichi Morikawa; Megumi Hato; Kenichi Higashino; Yasuro Shinohara; Naoya Sakamoto, HEPATOLOGY, 70, 1079A, 1079A, Oct. 2019
English, Summary international conference - ENTECAVIR TREATMENT OF HEPATITIS B VIRUS-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT, INCLUDING THOSE ON HEMODIALYSIS
Kazuharu Suzuki; Goki Suda; Taku Shigesawa; Akihisa Nakamura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto, HEPATOLOGY, 70, 314A, 314A, Oct. 2019
English, Summary international conference - C型肝炎患者の血清Angiopoietin-2値はDAAs治療後の肝線維化非改善例を予測する
川岸 直樹; 須田 剛生; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A653, A653, Oct. 2019
(一社)日本肝臓学会, Japanese - カルニチンは肝硬変患者における筋肉量減少を抑制する
大原 正嗣; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 川岸 直樹; 中井 正人; 荘 拓也; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A677, A677, Oct. 2019
(一社)日本肝臓学会, Japanese - 進行肝細胞癌に対するレンバチニブ投与症例からみた適格使用時期の検討
荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.2, A705, A705, Oct. 2019
(一社)日本肝臓学会, Japanese - 【進化する肝細胞癌の薬物療法-2019 Update(Part 2)】切除・ablation後のアジュバント試験 ニボルマブによる根治治療後の再発抑制試験(CheckMate 9DX trial)
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 79, 3, 461, 465, Sep. 2019
(株)アークメディア, Japanese - 増大傾向を認めた肝血管筋脂肪腫の一切除例
北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 折茂 達也; 神山 俊哉; 武冨 紹信; 杉野 弘和; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 46, 46, Sep. 2019
日本消化器病学会-北海道支部, Japanese - 急速な経過をたどった肉腫様肝癌の1例
山田 錬; 北潟谷 隆; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉; 清水 亜衣; 三橋 智子, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 59, 59, Sep. 2019
日本消化器病学会-北海道支部, Japanese - 門亢症を伴う肝硬変に対する薬物療法の進歩〜腹水・脳症・血栓など〜 リファキシミン投与前後でのNPT改善効果、Bacterial translocationマーカーの検討
中井 正人; 北潟谷 隆; 山田 錬; 重沢 拓; 鈴木 和治; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 70, 70, Sep. 2019
(一社)日本門脈圧亢進症学会, Japanese - 肝静脈-下大静脈ステント留置にて改善した4型Budd-Chiari症候群の一例
鈴木 和治; 中井 正人; 阿保 大介; 北潟谷 隆; 山田 錬; 中村 晃久; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 吉野 裕紀; 曽山 武士; 坂本 直哉, 日本門脈圧亢進症学会雑誌, 25, 3, 154, 154, Sep. 2019
(一社)日本門脈圧亢進症学会, Japanese - リファキシミン投与によるNPT改善効果とカルニチン製剤との比較
中井正人; 重沢拓; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 60, Supplement 1, A523, A523, 20 Apr. 2019
(一社)日本肝臓学会, Japanese - リファキシミン投与によるNPT改善効果とカルニチン製剤との比較
中井 正人; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 60, Suppl.1, A523, A523, Apr. 2019
(一社)日本肝臓学会, Japanese - Is It Possible to Improve Liver Fibrosis by Antiviral Therapy Against Hepatitis B Virus?
小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, Progress in Medicine, 39, 4, 405, 408, Apr. 2019
(株)ライフ・サイエンス, Japanese - 【B型肝炎治療におけるアンメットニーズ】肝線維化を戻すことは可能か
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, Progress in Medicine, 39, 4, 405, 408, Apr. 2019
(株)ライフ・サイエンス, Japanese - 肝性脳症治療の変遷 肝性脳症治療の最近の考え方 肝性脳症治療の流れと各薬剤の位置づけ
小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝胆膵, 78, 3, 379, 384, Mar. 2019
(株)アークメディア, Japanese - 当院におけるE型急性肝不全4例の検討
重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 45, 45, Mar. 2019
日本消化器病学会-北海道支部, Japanese - 肝細胞癌に対してレンバニチニブ導入後破壊性甲状腺炎を呈した一例
久々湊 雅; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 60, 60, Mar. 2019
日本消化器病学会-北海道支部, Japanese - 肝硬変様の形態を呈した肝サルコイドーシスの一例
中村 晃久; 重沢 拓; 鈴木 和治; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 124回, 62, 62, Mar. 2019
日本消化器病学会-北海道支部, Japanese - 肝疾患患者における筋肉量測定方法別の経時的変化
大原 正嗣; 重沢 拓; 中村 晃久; 鈴木 和治; 梅村 真知子; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A372, A372, Mar. 2019
(一財)日本消化器病学会, Japanese - 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
荘 拓也; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A415, A415, Mar. 2019
(一財)日本消化器病学会, Japanese - 肝疾患患者における筋肉量測定方法別の経時的変化
大原 正嗣; 重沢 拓; 中村 晃久; 鈴木 和治; 梅村 真知子; 川岸 直樹; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A372, A372, Mar. 2019
(一財)日本消化器病学会, Japanese - 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
荘 拓也; 須田 剛生; 重沢 拓; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 116, 臨増総会, A415, A415, Mar. 2019
(一財)日本消化器病学会, Japanese - 肝疾患患者における筋肉量測定方法別の経時的変化
大原正嗣; 重沢拓; 中村晃久; 鈴木和治; 梅村真知子; 川岸直樹; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 116, 2019 - 進行肝細胞癌に対するレンバチニブの4週/8週における治療効果と安全性の検討
荘拓也; 須田剛生; 重沢拓; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, 日本消化器病学会雑誌(Web), 116, 2019 - FPGおよびIPG法による標的タンパク質におけるN-結合型糖鎖解析法の開発
花松久寿; 小林隆史; 小川浩司; 羽藤愛美; 吉永知世; 森川賢一; 須田剛生; 荘拓也; 中井正人; 東野賢一; 沼田義人; 篠原康郎; 坂本直哉; 古川潤一, 日本糖質学会年会要旨集, 38th, 2019 - 進行肝細胞癌に対するレンバチニブの初期治療経験
荘拓也; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, Liver Cancer Journal, 10, Suppl.2, 55‐56, 56, 10 Dec. 2018
(株)メディカルレビュー社, Japanese - 進行肝細胞癌に対するレンバチニブの初期治療経験
荘 拓也; 須田 剛生; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 梅村 真知子; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, The Liver Cancer Journal, 10, Suppl.2, 55, 56, Dec. 2018
(株)メディカルレビュー社, Japanese - Sorafenib不応進行肝細胞癌におけるRegorafenibの初期使用経験
中村晃久; 中井正人; 重沢拓; 鈴木和治; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 3, A931, 25 Nov. 2018
Japanese - 核酸アナログによるウイルス制御下での肝発癌の検討
小川浩司; 重沢拓; 中村晃久; 鈴木和治; 川岸直樹; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 59, Supplement 2, A659, 20 Sep. 2018
Japanese - 高発癌リスク群HIV/HCV重複感染例に対するHCV治療
荘拓也; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 中井正人; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A707, 20 Sep. 2018
Japanese - 肝硬変症に伴う高アンモニア血症に対するリファキシミンの効果,安全性の検討
中井正人; 鈴木和治; 中村晃久; 大原正嗣; 川岸直樹; 梅村真知子; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A721, 20 Sep. 2018
Japanese - HCV肝炎治療高齢化時代における,HCV排除後LDL‐C上昇の動脈硬化リスクの検討
川岸直樹; 須田剛生; 鈴木和治; 中村晃久; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 2, A665, 20 Sep. 2018
Japanese - 急速に変貌する肝細胞癌の薬物療法2018 Update 免疫チェックポイント阻害剤と分子標的薬の併用療法 ソラフェニブvsアテゾリズマブ+ベバシズマブの第III相試験(IMbrave150試験)
小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝胆膵, 77, 2, 486‐490, 28 Aug. 2018
Japanese - 【急速に変貌する肝細胞癌の薬物療法2018 Update】 免疫チェックポイント阻害剤同士のコンビネーション治療 ソラフェニブvsアテゾリズマブ+ベバシズマブの第III相試験(IMbrave150試験)
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 77, 2, 486, 490, Aug. 2018
(株)アークメディア, Japanese - 【急速に変貌する肝細胞癌の薬物療法2018 Update】 免疫チェックポイント阻害剤同士のコンビネーション治療 ソラフェニブvsアテゾリズマブ+ベバシズマブの第III相試験(IMbrave150試験)
小川 浩司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝・胆・膵, 77, 2, 486, 490, Aug. 2018
(株)アークメディア, Japanese - 長期生存を目指した分子標的治療ほか 進行肝細胞癌に対するソラフェニブ治療不応例の検討
中村晃久; 小川浩司; 鈴木和治; 大原正嗣; 川岸直樹; 出水孝章; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, Liver Cancer Journal, 75‐76, 10 Jun. 2018
Japanese - 進行肝細胞癌に対するソラフェニブ治療不応例の検討
中村 晃久; 小川 浩司; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, The Liver Cancer Journal, Suppl.1, 75, 76, Jun. 2018
(株)メディカルレビュー社, Japanese - NASH/NAFLDの新知見 画像診断 Transient elastography
小川浩司; 中井正人; 荘拓也; 須田剛生; 森川賢一; 西田睦; 坂本直哉, 肝胆膵, 76, 4, 662‐667, 28 Apr. 2018
Japanese - 肝硬変症の成因別実態
小川浩司; 鈴木和治; 中村晃久; 川岸直樹; 大原正嗣; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 59, Supplement 1, A272, 20 Apr. 2018
Japanese - HBV感染者に対する核酸アナログ投与の脂質代謝に及ぼす影響の検討
鈴木和治; 須田剛生; 中村晃久; 大原正嗣; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 1, A486, 20 Apr. 2018
Japanese - DAAsによるHCV排除後の肝脂肪化・脂質代謝変化の包括的検討
川岸直樹; 鈴木和治; 中村晃久; 大原正嗣; 梅村真知子; 出水孝章; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 59, Supplement 1, A387, 20 Apr. 2018
Japanese - 成因別の肝発がんリスクの臨床的評価法の確立と治療介入 肝弾性度と肝脂肪量を用いた肝発がんリスク評価と高発がん危険群の囲い込み
森川 賢一; 荘 拓也; 坂本 直哉, 肝臓, 59, Suppl.1, A102, A102, Apr. 2018
(一社)日本肝臓学会, Japanese - 成因別の肝発がんリスクの臨床的評価法の確立と治療介入 肝弾性度と肝脂肪量を用いた肝発がんリスク評価と高発がん危険群の囲い込み
森川 賢一; 荘 拓也; 坂本 直哉, 肝臓, 59, Suppl.1, A102, A102, Apr. 2018
(一社)日本肝臓学会, Japanese - うっ血性肝硬変の診療における諸問題〜肝臓内科医が避けられない移行期医療を含めて〜 フォンタン術後肝合併症の検討
荘 拓也; 森川 賢一; 坂本 直哉, 肝臓, 59, Suppl.1, A181, A181, Apr. 2018
(一社)日本肝臓学会, Japanese - 肝臓の栄養管理 肝硬変患者に対するカルニチン投与による筋肉量への影響
大原 正嗣; 須田 剛生; 小川 浩司; 鈴木 和治; 中村 晃久; 川岸 直樹; 梅村 真知子; 出水 孝章; 中井 正人; 荘 拓也; 森川 賢一; 坂本 直哉, 日本病態栄養学会誌, 21, Suppl., S, 38, Jan. 2018
(一社)日本病態栄養学会, Japanese - Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C
N. Kawagishi; G. Suda; M. Onozawa; M. Kimura; O. Maehara; M. Ohara; T. Izumi; M. Umemura; J. Ito; M. Nakai; T. Sho; M. Natsuizaka; K. Morikawa; K. Ogawa; N. Sakamoto, JOURNAL OF VIRAL HEPATITIS, 24, 12, 1098, 1106, Dec. 2017
English - 肝硬変患者における血中亜鉛の検討
小川 浩司; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.3, A779, A779, Nov. 2017
(一社)日本肝臓学会, Japanese - 慢性肝疾患患者のそう痒症状に対するナルフラフィンの治療効果の検討
鈴木 和治; 中井 正人; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A788, A788, Nov. 2017
(一社)日本肝臓学会, Japanese - C型肝炎のDAAs治療における脂質、糖代謝の変化の検討
川岸 直樹; 鈴木 和治; 中村 晃久; 大原 正嗣; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A813, A813, Nov. 2017
(一社)日本肝臓学会, Japanese - 肝硬変患者における血中亜鉛の検討
小川 浩司; 鈴木 和治; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.3, A779, A779, Nov. 2017
(一社)日本肝臓学会, Japanese - 慢性肝疾患患者のそう痒症状に対するナルフラフィンの治療効果の検討
鈴木 和治; 中井 正人; 中村 晃久; 大原 正嗣; 川岸 直樹; 出水 孝章; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A788, A788, Nov. 2017
(一社)日本肝臓学会, Japanese - C型肝炎のDAAs治療における脂質、糖代謝の変化の検討
川岸 直樹; 鈴木 和治; 中村 晃久; 大原 正嗣; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.3, A813, A813, Nov. 2017
(一社)日本肝臓学会, Japanese - ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果と非著効例における薬剤耐性ウイルスの検討
荘拓也; 須田剛生; 大原正嗣; 出水孝章; 川岸直樹; 中井正人; 森川賢一; 伊藤淳; 山本義也; 小野雄司; 永坂敦; 寺下勝巳; 小林智絵; 古家乾; 坂本直哉, 肝臓, 58, Suppl.2, A575, A575, Sep. 2017
(一社)日本肝臓学会, Japanese - DAA治療非著効により獲得される耐性変異の検討
伊藤淳; 大原正嗣; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 58, Suppl.2, A589, A589, Sep. 2017
(一社)日本肝臓学会, Japanese - 肝硬変患者における筋肉量測定方法の検討
大原正嗣; 鈴木和治; 中村晃久; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 小川浩司; 坂本直哉, 肝臓, 58, Suppl.2, A633, A633, Sep. 2017
(一社)日本肝臓学会, Japanese - 核酸アナログ製剤によるHBs抗原の低下作用
小川浩司; 中村晃久; 鈴木和治; 大原正嗣; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 58, Suppl.2, A616, A616, Sep. 2017
(一社)日本肝臓学会, Japanese - NBNC肝癌の臨床的特徴
小川浩司; 中村晃久; 鈴木和治; 大原正嗣; 川岸直樹; 出水孝章; 梅村真知子; 中井正人; 荘拓也; 須田剛生; 森川賢一; 坂本直哉, 肝臓, 58, Suppl.2, A604, A604, Sep. 2017
(一社)日本肝臓学会, Japanese - ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果と非著効例における薬剤耐性ウイルスの検討
荘 拓也; 須田 剛生; 大原 正嗣; 出水 孝章; 川岸 直樹; 中井 正人; 森川 賢一; 伊藤 淳; 山本 義也; 小野 雄司; 永坂 敦; 寺下 勝巳; 小林 智絵; 古家 乾; 坂本 直哉, 肝臓, 58, Suppl.2, A575, A575, Sep. 2017
(一社)日本肝臓学会, Japanese - DAA治療非著効により獲得される耐性変異の検討
伊藤 淳; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A589, A589, Sep. 2017
(一社)日本肝臓学会, Japanese - NBNC肝癌の臨床的特徴
小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A604, A604, Sep. 2017
(一社)日本肝臓学会, Japanese - 核酸アナログ製剤によるHBs抗原の低下作用
小川 浩司; 中村 晃久; 鈴木 和治; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 58, Suppl.2, A616, A616, Sep. 2017
(一社)日本肝臓学会, Japanese - 肝硬変患者における筋肉量測定方法の検討
大原 正嗣; 鈴木 和治; 中村 晃久; 川岸 直樹; 出水 孝章; 梅村 真知子; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.2, A633, A633, Sep. 2017
(一社)日本肝臓学会, Japanese - ウイルソン病における各診断ガイドラインの有用性の検討
中井 正人; 森川 賢一; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 荘 拓也; 須田 剛生; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 114, 5, 839, 845, May 2017
(一財)日本消化器病学会, Japanese - NASH診療の現状と問題点 非アルコール性脂肪性肝疾患診断における問題点
小川 浩司; 荘 拓也; 坂本 直哉, 肝臓, 58, Suppl.1, A106, A106, Apr. 2017
(一社)日本肝臓学会, Japanese - RFA/TACE前後のM2BPGiの変化とRFA後再発予測因子としてのM2BPGiの有用性
中井 正人; 大原 正嗣; 川岸 直樹; 出水 孝章; 梅村 真知子; 伊藤 淳; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 58, Suppl.1, A352, A352, Apr. 2017
(一社)日本肝臓学会, Japanese - エキスパートオピニオン:超高齢者の肝胆膵疾患診療 超高齢者における病態の特性,治療の適応,治療の実際:肝疾患 C型肝炎
森川賢一; 荘拓也; 須田剛生; 坂本直哉, 肝胆膵, 74, 3, 385‐390, 28 Mar. 2017
Japanese - 【エキスパートオピニオン:超高齢者の肝胆膵疾患診療】 超高齢者における病態の特性、治療の適応、治療の実際 肝疾患 C型肝炎
森川 賢一; 荘 拓也; 須田 剛生; 坂本 直哉, 肝・胆・膵, 74, 3, 385, 390, Mar. 2017
(株)アークメディア, Japanese - C型肝炎の治療到達点と新たな課題 HIV/HCV重複感染の現状とIFN-based therapyおよびDAA therapyの治療効果
荘 拓也; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 114, 臨増総会, A59, A59, Mar. 2017
(一財)日本消化器病学会, Japanese - 肝炎ウイルス陽性者アラートシステム導入後の改善効果
小川 浩司; 川岸 直樹; 大原 正嗣; 出水 孝章; 梅村 真知子; 伊藤 淳; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 114, 臨増総会, A340, A340, Mar. 2017
(一財)日本消化器病学会, Japanese - Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
N. Kawagishi; G. Suda; M. Onozawa; M. Kimura; O. Maehara; M. Ohara; T. Izumi; M. Umemura; J. Ito; M. Nakai; T. Sho; M. Natsuizka; K. Morikawa; K. Ogawa; N. Sakamoto, JOURNAL OF HEPATOLOGY, 66, 1, S725, S726, 2017
English, Summary international conference - C型肝炎撲滅に向けた地域の取り組み 肝炎ウイルス陽性者アラートシステムによるC型肝炎受診率向上効果
小川 浩司; 荘 拓也; 坂本 直哉, 肝臓, 57, Suppl.3, A693, A693, Oct. 2016
(一社)日本肝臓学会, Japanese - 高齢者ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果・安全性の検討
荘 拓也; 須田 剛生; 大原 正嗣; 出水 孝章; 梅村 真知子; 川岸 直樹; 伊藤 淳; 中井 正人; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 57, Suppl.3, A776, A776, Oct. 2016
(一社)日本肝臓学会, Japanese - 【健診・検診・人間ドック読み方・進め方ガイドブック-今さら聞けない解釈の基本と対処】(第3章)検体検査 血液生化学検査 ビリルビン
荘 拓也; 坂本 直哉, 内科, 118, 3, 516, 520, Sep. 2016
(株)南江堂, Japanese - 核酸アナログ製剤によるHBs抗原の低下作用
小川 浩司; 大原 正嗣; 川岸 直樹; 梅村 真知子; 出水 孝章; 伊藤 淳; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 57, Suppl.2, A530, A530, Sep. 2016
(一社)日本肝臓学会, Japanese - ジェノタイプ2型C型肝炎・肝硬変に対するSofosbuvir(SOF)+Ribavirin(RBV)併用療法の治療効果の検討
荘 拓也; 山本 義也; 永坂 敦; 古家 乾; 吉田 純一; 常松 泉; 伊藤 淳; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 日本消化器病学会雑誌, 113, 臨増大会, A742, A742, Sep. 2016
(一財)日本消化器病学会, Japanese - 進行肝細胞癌におけるSorafenib+5-FU併用療法の検討
荘 拓也; 小川 浩司; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, The Liver Cancer Journal, 8, 1, 58, 59, Jun. 2016
(株)メディカルレビュー社, Japanese - FPD搭載IVRシステム導入後のHCCに対する超選択的Lip-TACEの治療成績
阿保 大介; 作原 祐介; 曽山 武士; 高橋 文也; 木村 輔; 工藤 與亮; 柿坂 達彦; 横尾 英樹; 神山 俊哉; 荘 拓也; 小川 浩司, IVR: Interventional Radiology, 31, 2, 175, 175, Jun. 2016
(一社)日本インターベンショナルラジオロジー学会, Japanese - 膿瘍形成を繰り返した魚骨腸管穿孔の1例
長島 一哲; 荘 拓也; 羽田 政平; 中積 宏之; 佐々木 尚英; 佐野 逸紀; 出水 孝章; 國枝 保幸, 日本消化器病学会雑誌, 113, 3, 451, 456, Mar. 2016
(一財)日本消化器病学会, Japanese - 肝移植後C型肝炎患者に対するダクラタスビル・アスナプレビル併用療法の検討
小川 浩司; 梅村 真知子; 出水 孝章; 伊藤 淳; 佐藤 史幸; 常松 聖司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉; 嶋村 剛, 肝臓, 56, Suppl.3, A981, A981, Nov. 2015
(一社)日本肝臓学会, Japanese - 肝細胞癌におけるKLF5による癌幹細胞制御機構
佐藤 史幸; 夏井坂 光輝; 前原 経; 浅野 彩華; 久保田 良政; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 大西 俊介; 坂本 直哉, 肝臓, 56, Suppl.3, A1002, A1002, Nov. 2015
(一社)日本肝臓学会, Japanese - 肝癌・非肝癌症例における肝弾性値の検討
荘 拓也; 小川 浩司; 出水 孝章; 梅村 真知子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 56, Suppl.3, A1010, A1010, Nov. 2015
(一社)日本肝臓学会, Japanese - 単純性脂肪肝と非アルコール性脂肪性肝炎の臨床的検討
寺下 勝巳; 小川 浩司; 伊藤 淳; 佐藤 史幸; 常松 聖司; 佃 曜子; 中井 正人; 荘 拓也; 須田 剛気; 森川 健一; 坂本 直哉, 肝臓, 56, Suppl.2, A756, A756, Sep. 2015
(一社)日本肝臓学会, Japanese - B型慢性肝炎に対するテノホビル(TDF)の初期使用経験と短期効果の検討
中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 荘 拓也; 須田 剛生; 森川 賢一; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.2, A760, A760, Sep. 2015
(一社)日本肝臓学会, Japanese - 非消化器系診療科における院内肝炎ウイルス陽性者の動向調査
小川 浩司; 伊藤 淳; 常松 聖司; 佐藤 史幸; 中井 正人; 荘 拓也; 須田 剛生; 森川 賢一; 坂本 直哉, 肝臓, 56, Suppl.2, A788, A788, Sep. 2015
(一社)日本肝臓学会, Japanese - Sorafenib導入後HCC症例に対する経動脈治療の検討
吉野 裕紀; 阿保 大介; 作原 祐介; 高橋 文也; 曽山 武士; 工藤 與亮; 柿坂 達彦; 横尾 英樹; 神山 俊哉; 小川 浩司; 荘 拓也; 夏井坂 光輝, IVR: Interventional Radiology, 30, 3, 273, 273, Sep. 2015
(一社)日本インターベンショナルラジオロジー学会, Japanese - 小児の肝疾患 臨床・研究のup to date 当院におけるFontan術後の肝合併症の現状
荘 拓也; 小川 浩司; 坂本 直哉, 日本消化器病学会雑誌, 112, 臨増大会, A637, A637, Sep. 2015
(一財)日本消化器病学会, Japanese - NS3、NS5AおよびNS5B阻害剤耐性変異とシメプレビル3剤併用療法における治療効果の検討
伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 荘 拓也; 須田 剛生; 夏井坂 光輝; 森川 賢一; 小川 浩司; 永坂 敦; 古家 乾; 宮城島 拓人; 坂本 直哉, 肝臓, 56, Suppl.1, A247, A247, Apr. 2015
(一社)日本肝臓学会, Japanese - 当科におけるC型肝炎SVR後の肝発癌症例の検討 発癌率と危険因子
中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 森川 賢一; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A262, A262, Apr. 2015
(一社)日本肝臓学会, Japanese - 肝動注化学療法における早期治療効果予測因子に関する検討
常松 聖司; 須田 剛生; 伊藤 淳; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 荘 拓也; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A285, A285, Apr. 2015
(一社)日本肝臓学会, Japanese - C型肝炎ウイルスの粒子形成・分泌機構の解明と関与する細胞性因子の解析
森川 賢一; 島崎 とも江; 伊藤 淳; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 56, Suppl.1, A318, A318, Apr. 2015
(一社)日本肝臓学会, Japanese - 各種肝疾患における肝弾性度の検討
荘 拓也; 小川 浩司; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 須田 剛生; 森川 賢一; 夏井坂 光輝; 坂本 直哉, 肝臓, 56, Suppl.1, A360, A360, Apr. 2015
(一社)日本肝臓学会, Japanese - ヒト初代B細胞におけるHCVcc感染
中井 正人; 伊藤 淳; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; フセイン・ハッサン・アリ; 松本 美佐子; 瀬谷 司; 坂本 直哉, 日本消化器病学会雑誌, 112, 臨増総会, A354, A354, Mar. 2015
(一財)日本消化器病学会, Japanese - エラストを臨床に活かす 当科におけるフィブロスキャン活用の現状
荘 拓也; 小川 浩司; 伊藤 淳; 佃 曜子; 寺下 勝巳; 中井 正人; 坂本 直哉; 工藤 悠輔; 西田 睦, 超音波医学, 42, 1, 83, 83, Jan. 2015
(一社)日本超音波医学会, Japanese - 【肝臓病診療のアップデート】 総論 肝機能検査の読み方、解釈、鑑別のコツ
荘 拓也; 坂本 直哉, 診断と治療, 102, 11, 1607, 1613, Nov. 2014
(株)診断と治療社, Japanese - 当院におけるフォンタン術後患者の肝合併症の現状
荘 拓也; 小川 浩司; 伊藤 淳; 佐藤 史幸; 常松 聖司; 佃 曜子; 寺下 勝巳; 中井 正人; 須田 剛生; 夏井坂 光輝; 坂本 直哉; 泉 岳; 武田 充人; 有賀 正, 肝臓, 55, Suppl.3, A855, A855, Oct. 2014
(一社)日本肝臓学会, Japanese - L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
佃 曜子; 伊藤 淳; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 中馬 誠; 坂本 直哉, 日本消化器病学会雑誌, 111, 臨増大会, A916, A916, Sep. 2014
(一財)日本消化器病学会, Japanese - 非代償性肝硬変に伴う胸腹水および肝腎症候群に対するトルバプタン使用例の検討
中井 正人; 伊藤 淳; 佃 曜子; 寺下 勝巳; 荘 拓也; 須田 剛生; 夏井坂 光輝; 小川 浩司; 坂本 直哉, 肝臓, 55, Suppl.2, A670, A670, Sep. 2014
(一社)日本肝臓学会, Japanese - 肝がん治療戦略のUp to Date 進行肝細胞癌に対する分子標的治療、肝動注療法の位置づけと今後の展開
中馬 誠; 山本 義也; 小川 浩司; 荘 拓也; 佃 曜子; 目黒 高志; 永坂 敦; 中村 路夫; 工藤 峰生; 武藤 修一; 上林 実; 曽我部 進; 宮城島 拓人; 中西 満; 坂本 直哉, 日本癌治療学会誌, 49, 3, 790, 790, Jun. 2014
(一社)日本癌治療学会, Japanese - 当科におけるHCV/HIV重複感染症の現状と抗HCV療法
荘 拓也; 中馬 誠; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 堀本 啓大; 須田 剛生; 夏井坂 光輝; 藤本 勝也; 遠藤 知之; 豊嶋 崇徳; 坂本 直哉, 肝臓, 55, Suppl.1, A213, A213, Apr. 2014
(一社)日本肝臓学会, Japanese - L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
佃 曜子; 伊藤 淳; 佐藤 史幸; 常松 聖司; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 須田 剛生; 夏井坂 光輝; 中馬 誠; 坂本 直哉, 肝臓, 55, Suppl.1, A240, A240, Apr. 2014
(一社)日本肝臓学会, Japanese - 肝内胆管癌におけるZEB1、EMT関連分子の臨床病理学的検討
寺下 勝巳; 畑中 佳奈子; 畑中 豊; 三橋 智子; 横尾 英樹; 大村 卓味; 石津 寛之; 永坂 敦; 山本 義也; 小川 浩司; 倉内 宣明; 豊田 秀徳; 熊田 卓; 金岡 祐次; 堀本 啓大; 荘 拓也; 夏井坂 光輝; 神山 俊哉; 武冨 紹信; 坂本 直哉, 肝臓, 55, Suppl.1, A335, A335, Apr. 2014
(一社)日本肝臓学会, Japanese - L-カルニチンのC型肝炎ウイルス増殖抑制効果に関する研究
佃 曜子; 須田 剛生; 佐藤 史幸; 常松 聖司; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 夏井坂 光輝; 中馬 誠; 坂本 直哉, 日本消化器病学会雑誌, 111, 臨増総会, A306, A306, Mar. 2014
(一財)日本消化器病学会, Japanese - Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions
Goki Suda; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Naoya Sakamoto, HEPATOLOGY, 60, 703A, 704A, 2014
English, Summary international conference - 進行肝癌の集学的治療 進行肝細胞癌に対する分子標的治療、肝動注療法の位置づけ
荘 拓也; 中馬 誠; 坂本 直哉, 肝臓, 54, Suppl.3, A673, A673, Nov. 2013
(一社)日本肝臓学会, Japanese - 低分化型肝細胞癌と肝内胆管癌の画像所見からの鑑別
荘 拓也; 中馬 誠; 常松 聖司; 佐藤 史幸; 寺下 勝巳; 佃 曜子; 中井 正人; 堀本 啓大; 須田 剛生; 夏井坂 光輝; 横尾 英樹; 神山 俊哉; 武富 紹信; 坂本 直哉, 肝臓, 54, Suppl.3, A860, A860, Nov. 2013
(一社)日本肝臓学会, Japanese - 分子標的薬と殺細胞性薬剤併用による治療効果増強の検証 高度進行肝癌に対する5-FU+ソラフェニブ併用療法の臨床第I相試験
荘 拓也; 中西 満; 中馬 誠; 中村 路夫; 永坂 敦; 小川 浩司; 山本 義也; 目黒 高志; 常松 聖司; 佐藤 史幸; 佃 曜子; 寺下 勝巳; 中井 正人; 小林 智絵; 夏井坂 光輝; 髭 修平; 坂本 直哉, The Liver Cancer Journal, 5, 2, 142, 143, Jun. 2013
(株)メディカルレビュー社, Japanese - 肝細胞癌におけるHeat shock transcription factor 1(HSF1)の分子標的治療としての可能性
中馬 誠; 坂本 直哉; 中井 彰; 髭 修平; 中西 満; 神山 俊哉; 横尾 英樹; 夏井坂 光輝; 須田 剛生; 荘 拓也; 堀本 啓大; 武冨 紹信; 松野 吉宏; 前田 愼, The Liver Cancer Journal, 5, 2, 146, 147, Jun. 2013
(株)メディカルレビュー社, Japanese - 低分化型肝細胞癌と肝内胆管癌の画像所見と鑑別
常松 聖司; 中馬 誠; 中西 満; 夏井坂 光輝; 須田 剛生; 荘 拓也; 小林 智絵; 寺下 勝巳; 佃 曜子; 佐藤 史幸; 横尾 英樹; 神山 俊哉; 武富 紹信; 坂本 直哉, 肝臓, 54, Suppl.1, A270, A270, Apr. 2013
(一社)日本肝臓学会, Japanese - 肝細胞癌におけるHSF1の役割(The role of HSF1 in hepatocellular carcinoma)
中馬 誠; 坂本 直哉; 中井 彰; 髭 修平; 中西 満; 夏井坂 光輝; 荘 拓也; 横尾 英樹; 中西 一彰; 神山 俊哉; 武冨 紹信; 藤井 元; 前田 愼, 日本癌学会総会記事, 71回, 432, 432, Aug. 2012
日本癌学会, English - 肝細胞癌に対する分子標的薬開発の基礎から臨床 肝細胞癌におけるHeat shock transcription factor 1(HSF1)の分子標的治療としての可能性
中馬 誠; 坂本 直哉; 髭 修平; 中西 満; 夏井坂 光輝; 荘 拓也; 小林 智絵; 寺下 勝巳; 佃 曜子; 常松 聖司; 中西 一彰; 横尾 英樹; 神山 俊哉; 武冨 紹信; 前田 愼, 肝臓, 53, Suppl.1, A118, A118, Apr. 2012
(一社)日本肝臓学会, Japanese - 高度進行肝癌に対する5-FU+ソラフェニブ併用療法の臨床第I相試験 分子標的薬と殺細胞性薬剤併用による治療効果増強の検証
中西 満; 中馬 誠; 髭 修平; 中村 路夫; 小川 浩司; 常松 聖司; 佃 曜子; 寺下 勝巳; 中井 正人; 小林 智絵; 荘 拓也; 山本 義也; 永坂 敦; 目黒 高志; 坂本 直哉, 肝臓, 53, Suppl.1, A406, A406, Apr. 2012
(一社)日本肝臓学会, Japanese - C型肝炎患者に対するリバビリン単独投与における貧血と血小板増加効果
小林 智絵; 髭 修平; 寺下 勝巳; 中井 正人; 堀本 啓大; 荘 拓也; 中西 満; 小川 浩司; 中馬 誠, 日本消化器病学会雑誌, 109, 臨増総会, A313, A313, Mar. 2012
(一財)日本消化器病学会, Japanese - ANEMIA AND THROMBOCYTOSIS INDUCED BY RIBAVIRIN MONOTHERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C
Tomoe Kobayashi; Shuhei Hige; Masato Nakai; Katsumi Terashita; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Makoto Chuma, HEPATOLOGY, 54, 872A, 873A, Oct. 2011
English, Summary international conference - 【症状からアプローチするプライマリケア】 食欲不振
浅香 正博; 荘 拓也, 日本医師会雑誌, 140, 特別2, S87, S91, Oct. 2011
日本医師会, Japanese - 肝細胞癌に対するラジオ波焼灼療法後の同亜区域内、亜区域外再発と生命予後の検討
荘 拓也; 中馬 誠; 中西 満; 堀本 啓大; 中井 正人; 小林 智絵; 寺下 勝巳; 髭 修平; 浅香 正博, 肝臓, 52, Suppl.2, A664, A664, Sep. 2011
(一社)日本肝臓学会, Japanese - 【新時代のウイルス性肝炎学 基礎・臨床研究の進歩】 B型肝炎 B型慢性肝炎に対する治療学の進歩 B型慢性肝炎に対するインターフェロン療法
髭 修平; 荘 拓也; 中西 満; 中馬 誠, 日本臨床, 69, 増刊4 新時代のウイルス性肝炎学, 481, 485, May 2011
(株)日本臨床社, Japanese - 検査値の読み方 C型肝炎のペグIFN/リバビリン併用治療効果、副作用に関連するヒト遺伝子多型-IL28BとITPA遺伝子変異
髭 修平; 小林 智絵; 中井 正人; 荘 拓也; 中西 満; 中馬 誠, 臨床消化器内科, 26, 5, 611, 615, Apr. 2011
(株)日本メディカルセンター, Japanese - Precore/Core promoter変異とB型肝炎の病態および抗HBV治療
中井 正人; 小林 智絵; 荘 拓也; 中西 満; 中馬 誠; 髭 修平, 肝臓, 52, Suppl.1, A292, A292, Apr. 2011
(一社)日本肝臓学会, Japanese - 非B非C型肝細胞癌症例の臨床的特徴
荘 拓也; 中馬 誠; 髭 修平, 肝臓, 52, Suppl.1, A411, A411, Apr. 2011
(一社)日本肝臓学会, Japanese - 【B型肝炎治療の最新戦略】 B型肝炎に対するIFN/核酸アナログ製剤の有効性
髭 修平; 中馬 誠; 中井 正人; 小林 智絵; 荘 拓也; 中西 満; 浅香 正博, 消化器内科, 52, 1, 108, 114, Jan. 2011
(有)科学評論社, Japanese - The role of hepatitis B virus core-related antigen for predicting the incidence of HCC
Mitsuru Nakanishi; Makoto Chuma; Shuhei Hige; Tomoe Kobayashi; Masato Nakai; Takuya Shou; Masahiro Asaka, Acta Hepatologica Japonica, 52, 6, 387, 389, 2011
(一社)日本肝臓学会, English - 非ウイルス性肝細胞癌の実態 非B非C型肝細胞癌症例の背景肝病変と臨床的特徴
荘 拓也; 中馬 誠; 髭 修平, 肝臓, 51, Suppl.3, A675, A675, Oct. 2010
(一社)日本肝臓学会, Japanese - HBV保有者高率地域におけるHBV関連肝癌の実態 HBコア関連抗原の有用性の検討も含めて
中西 満; 髭 修平; 小林 智絵; 荘 拓也; 中馬 誠; 浅香 正博, 肝臓, 51, Suppl.2, A526, A526, Sep. 2010
(一社)日本肝臓学会, Japanese - 非B非C型肝細胞癌の臨床的検討
荘 拓也; 中馬 誠; 中井 正人; 小林 智絵; 中西 満; 山本 義也; 髭 修平; 浅香 正博, 肝臓, 51, Suppl.2, A560, A560, Sep. 2010
(一社)日本肝臓学会, Japanese - 毛細血管拡張性運動失調関連遺伝子ATDCによる細胞増殖・アポトーシスの解析
荘 拓也, 北海道医学雑誌, 85, 3, 205, 212, May 2010
ATDCがTip60の機能にどのような影響を与えているかを生化学的および細胞生物学的手法により解析した。ATDCの結合蛋白質としてTip60を同定した。ATDCとTip60は細胞質で共局在し、ATDCの過剰発現ではTip60のプロテアソーム依存性の分離が促進された。ATDCはTip60によるp53の120番リジンのアセチル化を抑制し、UVによって誘導されるp53依存性アポトーシスを抑制した。細胞増殖アッセイ、フォーカス形性能アッセイおよびコロニー形性能アッセイによりATDCは癌遺伝子的に機能することが判明した。, 北海道医学会, Japanese - HCVコアアミノ酸置換とPEG-IFN/リバビリン併用療法施行C型慢性肝炎症例の検討
小林 智絵; 髭 修平; 荘 拓也; 中西 満; 中馬 誠; 浅香 正博; 永坂 敦; 小川 浩司; 山本 義也, 肝臓, 51, Suppl.1, A226, A226, Apr. 2010
(一社)日本肝臓学会, Japanese - Others症例に対するペグインターフェロン・リバビリン併用療法の検討
小林 智絵; 髭 修平; 荘 拓也; 中西 満; 中馬 誠; 浅香 正博; 永坂 敦; 山本 義也, 肝臓, 51, Suppl.1, A280, A280, Apr. 2010
(一社)日本肝臓学会, Japanese - 1型高ウイルス量C型肝炎に対するPEG-IFN/RBV併用療法の有効性の検討
小林 智絵; 髭 修平; 荘 拓也; 中西 満; 中馬 誠; 浅香 正博; 小川 浩司; 山本 義也; 永坂 敦, 日本消化器病学会雑誌, 107, 臨増総会, A223, A223, Mar. 2010
(一財)日本消化器病学会, Japanese - 検査値の読み方 慢性腎不全合併C型慢性肝炎患者の血清トランスアミナーゼ値
髭 修平; 小林 智絵; 荘 拓也; 中西 満; 中馬 誠; 浅香 正博, 臨床消化器内科, 25, 1, 119, 123, Dec. 2009
(株)日本メディカルセンター, Japanese - 【消化器癌の予防】 肝細胞癌の予防 肝細胞癌根治後の再発に関するHBV DNA量の影響、再発予防に対する抗ウイルス薬の関与
中馬 誠; 髭 修平; 中西 満; 荘 拓也; 小林 智絵; 神山 俊哉; 中西 一彰; 目黒 高志; 永坂 敦; 山本 義也; 浅香 正博, The GI Forefront, 5, Suppl., 165, 168, Nov. 2009
(株)メディカルレビュー社, Japanese - HEPATITIS B VIRUS CORE-RELATED ANTIGEN AS A USEFUL MARKER FOR THE COMPREHENSION OF HBV STATUS IN HEPATOCYTES
Shuhei Hige; Makoto Chuma; Tomoe Kobayashi; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Masahiro Asaka, HEPATOLOGY, 50, 4, 979A, 979A, Oct. 2009
English, Summary international conference - 検査値の読み方 HCV coreアミノ酸置換 インターフェロン治療効果との関連性
髭 修平; 小林 智絵; 荘 拓也; 中西 満; 中馬 誠; 浅香 正博, 臨床消化器内科, 24, 9, 1301, 1305, Jul. 2009
(株)日本メディカルセンター, Japanese - 【肝胆膵の癌に対する放射線療法】 高度脈管腫瘍栓を伴う進行肝癌に対する動体追跡照射併用肝動注療法の有用性
中馬 誠; 白土 博樹; 田口 大志; 山本 義也; 荘 拓也; 山本 桂子; 夏井坂 光輝; 山本 洋一; 中西 満; 髭 修平; 浅香 正博, 胆と膵, 28, 臨増特大, 735, 739, Oct. 2007
医学図書出版(株), Japanese - 硬化性胆管炎を伴った自己免疫性膵炎の一例
中井 正人; 永坂 敦; 藤澤 孝志; 才川 大介; 荘 拓也; 横山 仁; 佐野 公昭; 西川 秀司; 樋口 晶文, 市立札幌病院医誌, 67, 1, 59, 65, Sep. 2007
市立札幌病院, Japanese - PNA-MGB法によるB型肝炎再燃とラミブジン耐性株の定量的・経時的検討
山本 洋一; 髭 修平; 荘 拓也; 夏井坂 光輝; 中西 満; 中馬 誠; 吉田 繁; 浅香 正博, 肝臓, 48, Suppl.1, A149, A149, Apr. 2007
(一社)日本肝臓学会, Japanese - ラミブジン投与B型慢性肝疾患症例の有効性および耐性出現の予測
荘 拓也; 髭 修平; 山本 洋一; 夏井坂 光輝; 中西 満; 中馬 誠; 浅香 正博, 肝臓, 48, Suppl.1, A251, A251, Apr. 2007
(一社)日本肝臓学会, Japanese - 検査値の読み方 ラミブジン投与B型肝炎症例の耐性株出現予測におけるウイルスマーカーの評価
髭 修平; 荘 拓也; 山本 洋一; 中西 満; 中馬 誠; 浅香 正博, 臨床消化器内科, 22, 5, 607, 611, Apr. 2007
(株)日本メディカルセンター, Japanese - PNA-MGB法によるB型肝炎再燃時におけるラミブジン耐性株の定量的検討
山本 洋一; 髭 修平; 荘 拓也; 夏井坂 光輝; 中西 満; 中馬 誠; 吉田 繁; 浅香 正博, 日本消化器病学会雑誌, 104, 臨増総会, A109, A109, Mar. 2007
(一財)日本消化器病学会, Japanese - Quantification of hbv mutants against lamivudine by the PNA-MGB method during the course of breakthrough hepatitis
Y. Yamamoto; S. Hige; T. Sho; M. Natsuizaka; M. Nakanishi; M. Chuma; S. Yoshida; M. Asaka, JOURNAL OF HEPATOLOGY, 46, S199, S199, 2007
English, Summary international conference - B型慢性肝炎治療の新しいパラダイム HBe抗原陽性慢性肝炎に対する抗ウイルス療法 IFN・LAM併用療法の有用性
中馬 誠; 髭 修平; 中西 満; 夏井坂 光輝; 山本 洋一; 小原 俊央; 荘 拓也; 永坂 敦; 浅香 正博, 肝臓, 47, Suppl.3, 533, 533, Nov. 2006
(一社)日本肝臓学会, Japanese - Peptide nucleic acid clumpingとMinor groove binderプローブ法併用によるHBV-DNAの定量
山本 洋一; 髭 修平; 荘 拓也; 夏井坂 光輝; 中西 満; 中馬 誠; 浅香 正博, 肝臓, 47, Suppl.3, 548, 548, Nov. 2006
(一社)日本肝臓学会, Japanese - HIV/HCV重複感染症例に対する抗HCV療法の現状
荘 拓也; 髭 修平; 夏井坂 光輝; 中西 満; 中馬 誠; 近藤 健; 太田 秀一; 橋野 聡; 浅香 正博; 今村 雅寛; 藤本 勝也, 肝臓, 47, Suppl.3, 574, 574, Nov. 2006
(一社)日本肝臓学会, Japanese - HIV/HCV重複感染症例に対する抗HCV療法の現状
荘 拓也; 髭 修平; 夏井坂 光輝; 中西 満; 加畑 馨; 中馬 誠; 近藤 健; 太田 秀一; 橋野 聡; 渡部 恵子; 大野 稔子; 浅香 正博; 田中 淳司; 今村 雅寛; 藤本 勝也; 佐藤 典宏; 小池 隆夫, 日本エイズ学会誌, 8, 4, 346, 346, Nov. 2006
日本エイズ学会, Japanese - MGBプローブ法によるHBV変異株の定量
山本 洋一; 髭 修平; 荘 拓也; 夏井坂 光輝; 小川 浩司; 中西 満; 中馬 誠; 吉田 繁; 浅香 正博, 肝臓, 47, Suppl.2, A389, A389, Sep. 2006
(一社)日本肝臓学会, Japanese - PSE vs脾摘術 部分的脾動脈塞栓術の12例17回の経験
川西 輝明; 高柳 俊明; 吉田 暁正; 松嶋 喬; 荘 拓也; 中西 満; 関谷 千尋, 日本門脈圧亢進症学会雑誌, 12, 1, 40, 40, Aug. 2006
(一社)日本門脈圧亢進症学会, Japanese - 胃原発anaplastic large cell lymphomaの1例
荘 拓也; 横山 仁; 永坂 敦; 佐野 公昭; 西川 秀司; 樋口 晶文; 高田 明生; 武内 利直, Gastroenterological Endoscopy, 48, Suppl.1, 737, 737, Apr. 2006
(一社)日本消化器内視鏡学会, Japanese - イレウスを呈したPOEMS症候群の一例
藤澤 孝志; 西川 秀司; 荘 拓也; 横山 仁; 永坂 敦; 佐野 公昭; 樋口 晶文; 高田 明生; 佐藤 英俊, Gastroenterological Endoscopy, 48, Suppl.1, 772, 772, Apr. 2006
(一社)日本消化器内視鏡学会, Japanese - 食道癌肉腫の2例
横山 仁; 荘 拓也; 永坂 敦; 佐野 公昭; 西川 秀司; 樋口 晶文; 小川 弥生; 武内 利直, Gastroenterological Endoscopy, 48, Suppl.1, 819, 819, Apr. 2006
(一社)日本消化器内視鏡学会, Japanese - 血管免疫芽球型T細胞リンパ腫(AILT)様リンパ節腫脹を伴った薬剤性過敏症症候群(DIHS)の1例
川村 詔導; 佐々木 春喜; 阿部 雅一; 筒井 理裕; 渡辺 豊; 児嶋 美朝; 蔭山 博司; 安齋 治一; 葭内 史朗; 平山 剛; 荘 拓也; 佐藤 諭美; 古屋 和彦; 横田 浩一; 山中 快子; 池田 仁; 田原 正彦, 函館中央病院医誌, 8〜9, 13, 17, Jun. 2005
38歳男.5年前に頭部打撲による脳内血腫の除去術後からフェニトインを服用している.また,2ヵ月前に痙攣発作が出現したため,カルバマゼピンを追加投与されいた.今回,右側頸部リンパ節腫脹に続き高熱を発し近医を受診,検査所見から伝染性単核球症を疑われ紹介来院となった.初診時検査所見では肝機能異常と炎症所見を認め,膿瘍を伴う炎症性リンパ節腫大と診断してミノマイシン・ダラシンの静注とロキニン内服を開始した.翌日から粟粒大の発疹が上半身に出現,さらに4日後には解熱傾向は認めたが皮疹が全身に拡大したため薬剤性過敏症候群(DIHS)と診断し,リンパ節生検目的で入院となった.生検結果は血管免疫芽球型T細胞リンパ腫(AILT)様で,カルバマゼピンによるリンパ節腫脹の病理所見に類似していた.カルバマゼピン中止後約2週間で紅斑や全身浮腫が消失し4週間後には検査所見も回復しが,カルバマゼピンとミノマイシン中止には約10日間あり,本症例はこれら2薬剤によるDIHSの可能性が示唆された, 函館中央病院, Japanese - 過去10年間に経験した多発性骨髄腫84例の臨床的検討
川村 詔導; 佐々木 春喜; 阿部 雅一; 平山 剛; 佐藤 諭美; 荘 拓也; 葭内 史朗; 三浦 慶昭; 児嶋 美朝; 安斎 治一; 蔭山 博司; 渡辺 豊; 筒井 理裕, 道南医学会誌, 40, 3, 6, Mar. 2005
1994年4月〜2004年3月に経験した多発骨髄腫84症例について臨床的に検討した.女性が多く,年齢は男女共に70歳代が最も多かった.受診契機は腰痛の32%を含め骨痛が66%と最も多く,ついで高蛋白や貧血などの検査値の異常が15%であった.治療方法は,1994年から現在までメルファランとプレドニンとの併用療法,MP療法,VAD療法,ROAD-IN療法の4治療療法のいずれかを初回治療に用い,2001年からビスフォスフォネートの点滴静注を併用し,2003年からサリドマイド或いは幹細胞移植を行っている.生存期間は,病型別,治療別で有意差はなかった.合併症として帯状疱疹が9例に認められ,二次発癌は84例中2例に認められた, 道南医学会, Japanese
- 医学総論, 2024年, 博士後期課程, 医学研究科
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 肝癌のFGFR4-CXCL9 axis を介した免疫チェックポイント阻害剤耐性化機構の解析
科学研究費助成事業
01 Apr. 2024 - 31 Mar. 2027
荘 拓也; 坂本 直哉; 須田 剛生
日本学術振興会, 基盤研究(C), 北海道大学, 24K11142 - 肝癌幹細胞の維持・免疫寛容機構の解明と治療最適化の検討
科学研究費助成事業
01 Apr. 2021 - 31 Mar. 2024
荘 拓也; 坂本 直哉; 須田 剛生
肝癌の難治性の原因の一旦に肝癌幹細胞(CSCs)が関与するとの仮説ものもと、肝癌幹細胞の研究を行った。その中で、肝癌幹細胞維持に重要なファクターとしてKLF5が強く関与する可能性をRNA-sequence data をもとに明らかにした。続いてその恒常発現細胞を樹立、同細胞株を用いて検討を行い肝癌CSCs維持についての検討をFGFシグナルに着目して行った。siRNA, receptor 特異的な阻害剤を用いる事によりFGFR4でなくFGFR1-3シグナルがCSCs維持に重要である事を見出した。更に、現在までに、sorafenib と殺細胞性抗がん剤との併用療法の実臨床での相乗効果は明らかにされていない為にその原因を検索する為に肝癌細胞にsofafenib, sorafenib+5FUを添加して検討するとSorafenib +5FU 群ではCSCs populationが増加する事が明らかとなった。一方で、FGFR1-3阻害活性を有するlenvatinib と殺細胞性抗がん剤5FUを添加して検討するとlenvatinib +5FU 群ではCSCs populationが減少させながら相乗的な抗腫瘍効果を発揮する事が明らかとなった。同知見に基づきKLF5KR細胞マウスXenograft modelに、lenvatinib または、sorafenib +5FU併用療法 が行われた腫瘍を摘出し、サイズの比較、腫瘍細胞のFACS解析にてCSCsポピュレーションの変化を観察を行った。FGFR1-3 阻害によるCSCs減少により殺細胞性に対する感受性が上昇し、殺細胞性抗がん剤との併用が相乗効果を示すことがin vivoにても明らかになれば、現在までその有効性が十分に示されていない、経動脈的な肝癌治療とmultikinase 阻害剤併用療法の有効性を示された
日本学術振興会, 基盤研究(C), 北海道大学, 21K07953
